PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 1Title Page
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO 
COMPARE THE PHARMACOKINETICS OF PF-07923568 IN ADULT 
PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT 
RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT
Study Intervention Number: PF-07923568
Study Intervention Name: [CONTACT_486836]: [ADDRESS_625575]/CTIS Number: NA
ClinicalTrials.gov ID: Not available
Pediatric Investigational Plan Number: NA
Protocol Number: C5241012
Phase: 1
Brief Title: A Study to Investigate the Effects of Hepatic Impairment on the 
Pharmacokinetics of PF-07923568
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be promptly notified.
090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 2Document History
Document Version Date
Original protocol 23 Februar y2023090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....8
1. PROTOCOL  SUMMARY.....................................................................................................9
1.1. Synopsis .................................................................................................................. ..9
1.2. Schema .................................................................................................................... 15
1.3. Schedule of Activities .............................................................................................16
2. INTRODUCTION ...............................................................................................................1 9
2.1. Study R ationale .......................................................................................................19
2.2. Background .............................................................................................................19
2.2.1. Nonclinical Pharmacology..........................................................................202.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................202.2.3. Nonclinical Safety ......................................................................................212.2.4. Clinical Overview.......................................................................................22
2.3. Benefit/Risk Assessment.........................................................................................24
2.3.1. Risk Assessment .........................................................................................242.3.2. Benefit Assessment.....................................................................................262.3.3. Overall Benefit/Risk Conclusion................................................................26
3. OBJECTIVES AND ENDPOINTS .....................................................................................264. STUDY DESIGN................................................................................................................ .27
4.1. Overall Design.........................................................................................................274.2. Scientific Rationale for Study Design.....................................................................28
4.2.1. Choice of Contraception/Barrier Requirements .........................................304.2.2. Collection of Retained Research Samples..................................................30
4.3. Justification for Dose ..............................................................................................304.4. End of Study Definition ..........................................................................................31
5. STUDY POPULATION ......................................................................................................31
5.1. Inclusion Criteria.....................................................................................................31
5.1.1. Participants in All Groups ..........................................................................315.1.2. Additional Inclusion Criteria for Group 1 Only (without HI).....................32
5.1.3. Additional Inclusion Criteria for Groups 2-4 Only (Mild, Moderate, 
and Severe HI) .................................................................................................33
5.2. Exclusion Criteria....................................................................................................33090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 45.2.1. Participants in All Groups ..........................................................................33
5.2.2. Additional Exclusion Criteria for Group 1 Only (without HI) ...................35
5.2.3. Additional Exclusion Criteria for Groups 2-4 Only (Mild, Moderate, 
and Severe HI) .................................................................................................36
5.3. Lifestyle Cons iderations..........................................................................................37
5.3.1. Contraception..............................................................................................375.3.2. Meals and Dietary Restrictions...................................................................375.3.3. Caffeine, Alcohol, and Tobacco .................................................................385.3.4. Activity .......................................................................................................38
5.4. Screen Failures ........................................................................................................39
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY .................................39
6.1. Study Intervention(s) Administered ........................................................................39
6.1.1. Administration ............................................................................................40
6.2. Preparation, Handling, Storage, and Accountability...............................................40
6.2.1. Preparation and Dispensing ........................................................................41
6.3. Assignment to Study Intervention...........................................................................426.4. Blinding.................................................................................................................. .42
6.4.1. Blinding of Participants ..............................................................................426.4.2. Blinding of Site Personnel..........................................................................426.4.3. Blinding of the Sponsor..............................................................................42
6.5. Study Intervention Compliance...............................................................................426.6. Dose Modification...................................................................................................436.7. Continued Access to Study Intervention After the End of the Study......................436.8. Treatment of Overdose............................................................................................436.9. Prior and Concomitant Therapy ..............................................................................43
6.9.1. Participants in Group 1 Only (without Hepatic impairment) .....................446.9.2. Participants in Groups 2-4 Only (Hepatic Impairment) .............................446.9.3. Rescue Medicine.........................................................................................44
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL...........................................................................45
7.1. Discontinuation of Study Intervention ....................................................................457.2. Participant Discontinuation/Withdrawal from the Study........................................45090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 57.2.1. Withdrawal of Consent...............................................................................[ADDRESS_625576] to Follow-up ....................................................................................................46
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................46
8.1. Administrative Procedures ......................................................................................468.2. Efficacy Assessments..............................................................................................478.3. Safety Assessments .................................................................................................47
8.3.1. Physical Examinations................................................................................478.3.2. Vital Signs ..................................................................................................48
[IP_ADDRESS]. Blood Pressure and Pulse Rate..................................................48
8.3.3. Electrocardiograms.....................................................................................498.3.4. Clinical Safety La boratory Asse ssments ....................................................49
8.3.5. COVID-19 Specific Assessments...............................................................508.3.6. Pregnancy Testing ......................................................................................50
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................50
8.4.1. Time Period and Frequency for Collecting AE and SAE Information.......51
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................52
8.4.2. Method of Detecting AEs and SAEs ..........................................................528.4.3. Follow-Up of AEs and SAEs......................................................................528.4.4. Regulatory Reporting Requirements for SAEs...........................................538.4.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................53
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................55
8.4.6. Cardiovascular and Death Events...............................................................558.4.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_625577].............................................................56
[IP_ADDRESS]. Lack of Efficacy ........................................................................56
8.4.9. Medical Device Deficiencies......................................................................568.4.10. Medication Errors .....................................................................................56090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 68.5. Pharmacokinetics ....................................................................................................57
8.5.1. Plasma for Analysis of PF-07923568.........................................................57
8.6. Genetics.................................................................................................................. .58
8.6.1. Specified Genetics ......................................................................................588.6.2. Retained Research Samples for Genetics ...................................................58
8.7. Biomarkers ..............................................................................................................58
8.7.1. Specified Gene Expression (RNA) Research .............................................588.7.2. Specified Protein Research .........................................................................588.7.3. Specified Metabolomic Research ...............................................................588.7.4. Retained Research Samples for Biomarkers...............................................58
8.8. Immunogenicity Assessments .................................................................................598.9. Health Economics ...................................................................................................59
9. STATISTICAL C ONSIDERATIONS ................................................................................59
9.1. Statistical Hypotheses .............................................................................................599.2. Analysis Sets ...........................................................................................................599.3. Statistical Analyses .................................................................................................60
9.3.1. General Considerations...............................................................................60
[IP_ADDRESS]. Analyses for PK Endpoints .......................................................60
9.3.2. Primary Endpoint(s) Analysis.....................................................................60
[IP_ADDRESS]. Definition of Endpoint(s) ..........................................................[IP_ADDRESS]. Main Analytical Approach ........................................................[IP_ADDRESS]. Supplementary Analyses ...........................................................61
9.3.3. Secondary Endpoint Analysis - Safety Analyses........................................62
[IP_ADDRESS]. Electrocardiogram Analyses......................................................62
9.3.4. Tertiary/Exploratory Endpoint(s) Analysis ................................................62
[IP_ADDRESS]. Biomarkers ................................................................................62
9.3.5. Other Analyses............................................................................................63
9.4. Interim Analyses .....................................................................................................639.5. Sample Size Determination.....................................................................................63
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................64
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............64090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 710.1.1. Regulatory and Ethical Considerations ....................................................64
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................64
10.1.2. Financial Disclosure .................................................................................6510.1.3. Informed Consent Process ........................................................................6510.1.4. Data Protection .........................................................................................6610.1.5. Committees Structure ...............................................................................66
[IP_ADDRESS]. Data Monitoring Committee ...................................................66
10.1.6. Dissemination of Clinical Study Data ......................................................6710.1.7. Data Qualit y Assurance ............................................................................68
10.1.8. Source Documents....................................................................................6910.1.9. Study and Site Start and Closure ..............................................................6910.1.10. Publication Policy...................................................................................7010.1.11. Sponsor’s Medically Qualified Individual..............................................71
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7210.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................73
10.3.1. Definition of AE .......................................................................................7310.3.2. Definition of an SAE ................................................................................7410.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................76
10.3.4. Reporting of SAEs....................................................................................79
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................80
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................8010.4.2. Female Participant Reproductive Inclusion Criteria.................................8110.4.3. Woman of Childbearing Potential ............................................................8110.4.4. Contraception Methods.............................................................................82
10.5. Appendix 5: Genetics ............................................................................................8410.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......8510.7. Appendix 7: Kidney Saf ety: Monitoring Guidelines ............................................87
10.7.1. Laboratory Assessment of Change in Kidney Function and 
Detection of Kidney Injury ..............................................................................87
10.7.2. Age-Specific Kidney Function Calculation Recommendations...............87090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page [IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD-EPI 
[INVESTIGATOR_185560]9..........................................................................................87
10.7.3. Adverse Event Grading for Kidney Safety Laboratory 
Abnormalities...................................................................................................87
10.8. Appendix 8: ECG Findings of Potential Clinical Concern ...................................8810.9. Appendix 9: Prohibited Concomitant Medications That May Result in 
Drug-Drug Interaction (DDI) ....................................................................................90
10.10. Appendix 10: Child-Pugh Classification of Liver Dysfunction..........................9210.11. Appendix 11: Abbreviations ...............................................................................[ADDRESS_625578] OF TABLES
Table 1. Study Sche dule of Activities ....................................................................17
Table 2. Completed PF-07923568 Studies .............................................................22Table 3. Hepatic Function Categories Based on Child-Pugh Score .......................27Table 4. Plasma PK Parameters..............................................................................60Table 5. Expected Widths of the 90% CIs (with 80% Coverage Probability) 
for Different Possible Estimated Effects ..................................................63
Table 6. Protocol-Required Safety Laboratory Assessments .................................72Table 7. Scoring for Child-Pugh Classification
10...................................................92
Table 8. Derivation of Child-Pugh Classification Score ........................................92Table 9. Determination of Encephalopathy Grade .................................................92090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 91. PROTOCOL SUMMARY
1.1. SynopsisProtocol Title:
A Phase 1, Open-Label, Single-Dose, Parallel Group Study to Compare the Pharmacokinetics 
of PF-07923568 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment
Brief Title:A Study to Investigate the Effects of Hepatic Impairment on the Pharmacokinetics of 
PF-07923568
Regulatory Agency Identification Number(s):
US IND Number: [ADDRESS_625579]/CTIS Number: NA
ClinicalTrials.gov ID: Not available
Pediatric Investigational Plan Number: NA
Protocol Number: C5241012
Phase: 1
Rationale:
The primary purpose of this study is to characterize the effect of varying degrees of HI on the 
plasma PK of PF-07923568 following administration of a single oral dose of PF-07923568.
Objectives and Endpoints:
Objectives Endpoints
Primary: Primary:
!To compare the PK of PF-07923568 following administration 
of a single oral dose in adult participants with varying degrees 
of HI relative to age- and body weight-matched participants 
without HI.!Plasma: C max, AUC lastor AUC inf*, as data 
permit.
Secondary: Secondary:
!To evaluate the safety and tolerability of a single oral dose of 
PF-07923568 when administered to adult participants with varying degrees of HI and in age- and body weight-matched participants without HI.!Assessment of TEAEs, clinical laboratory 
abnormalities, vital signs, ECG parameters.
* AUC lastwill be treated as primary endpoints if data do not permit robust estimation of AUC inf, otherwise they will be 
treated as tertiary endpoints.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge 1 0 O ver all Desi g n :
T his is a n o pe n -la bel, si n gle -d ose, parallel -gr o u p , m ulti ce nter st u d y  t o i n vesti gate t he effect 
of var y i n g de grees of he patic f u ncti o n o n t he plas ma P K of P F - 0 7 9 2 3 5 6 8 after a si n gle, oral 
m g d ose a d mi nistere d i n t he fe d state (sta n dar d brea kfast) . Safet y a n d t olera bilit y  will be 
e val uate d t hr o u g h o ut t he st u d y .
N u m ber of P artici p a nts: 
Ap pr o xi matel y  [ADDRESS_625580] u d y  i nter ve nti o n. 
N ote: " E nr olle d" mea ns a partici pa nt's, or t heir le gall y  a ut h orize d re prese ntati ve’s, a gree me nt 
t o partici pate i n a cli nical st u d y  f oll o wi n g c o m pleti o n of t he i nf or me d c o nse nt pr ocess a n d 
assi g n me nt t o st u d y  i nter ve nti o n . A partici pa nt will be c o nsi dere d e nr olle d if t he i nf or me d 
c o nse nt is n ot wit h dra w n pri or t o partici pati n g i n a n y  st u d y  acti vit y after scree ni n g .P ote ntial 
partici pa nts w h o are scree ne d f or t he p ur p ose of deter mi ni n g eli gi bilit y  f or t he st u d y , b ut d o 
n ot partici pate i n t he st u d y, are n ot c o nsi dere d e nr olle d, u nless ot her wise s pecifie d b y t he 
pr ot oc ol. 
St u d y P o p ul ati o n :
K e y  i ncl usi o n a n d e xcl usi o n cr iteria are liste d bel o w: 
Ke y I ncl usi o n Criteri a 
Partici pa nts m ust meet t he f oll o wi n g k e y  i ncl usi o n criteria t o be eli gi ble f or st u d y  
e nr oll me nt: 
All Gr o u p s
Male s or fe male sbet wee n t he a ges of 1 8 ( or t he mi ni m u m c o u ntr y -s pecific a ge of 
c o nse nt if > 1 8) a n d 7 5 ye ars , i ncl usi ve at t he scree ni n g visit .
Willi n g a n d a ble t o c o m pl y  wit h all sc he d ule d visits, treat me nt pla n, la b orat or y tests, 
lifest y le c o nsi derati o ns, a n d ot her st u d y  pr oce d ures .
BMI of 1 7. 5 t o 3 8. 0 k g/ m 2, i ncl usi ve ,a n d a t otal b o d y  wei g ht > 5 0 k g ( 1 1 0 l b) .
Ca pa ble of gi vi n g si g ne d i nf or me d c o nse nt .
A d diti o n al f or Gr o u p 1 O nly (wit h o ut HI )
At scree ni n g, n o cli nicall y  rele va nt a b n or malities i de ntifie d b y  a detaile d me dical 
hist or y , c o m plete p h y sical e xa mi nati o n , i ncl u d i n g B P a n d p ulse rate meas ure me nt, 
sta n dar d 1 2- lea d E C G a n d cli nical la b orat or y  tests .0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 11!At screening, meet the demographic-matchi ng criteria, including body weight within
±15 kg and age within ±10 years, of the average of the pooled hepatic impairment 
groups, as provided by [CONTACT_456].
!No known or suspected hepatic impairment and meet all the following criteria based 
on screening laboratory tests: ALT ≤ ULN, AST ≤ ULN, T bili ≤ULN, albumin 
≤ULN, and PT ≤ULN.
Additional for Groups 2-4 Only (Mild, Moderate, and Severe HI)
!Stable hepatic impairment that meets criteria for Class A, B, or C of the Child-Pugh 
classification with no clinically significant change in disease status within 28 days before screening.
!Stable concomitant medications for the management of individual participant’s 
medical history.
Key Exclusion CriteriaParticipants with any of the following characteristics/conditions will be excluded:All Groups
!Any condition possibly affecting drug absorption (eg, prior bariatric surgery, 
gastrectomy, ileal resection).
!At screening, a positive result for HIV antibodies.
!History of surgery that would be expected to alter absorption, distribution, 
metabolism, or excretion properties of PF-07923568 (eg, status post portacaval shunt surgery).
!Other medical or psychiatric condition or laboratory abnormality that may increase 
the risk of study participation or make the participant inappropriate for the study.
!Use of specific prohibited prior/concomitant therapi[INVESTIGATOR_486807] 30 days (or local requirement) or 5 half-lives (whichever longer), or 14 days plus 5 half-lives for moderate and strong CYP3A inducers or time-dependent inhibitors, before study dose.
!eGFR <60 mL/min/1.73m
2(calculated with the 2021 CKD-EPI [INVESTIGATOR_185572]-Scys combined 
equation) at screening.
!A positive urine drug test at screening or Day -1; however, participants in 
Groups 2-4, only , who have been medically prescribed medications and report use at 
screening may be allowed after sponsor approval.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 12!At screening orDay -1, a positive breath alcohol test.
!For females, pregnancy, as indicated by a positive serum pregnancy test at screening 
and/or positive urine pregnancy test in women of childbearing potential at Day -1.
Additional Group 1 Only (without HI)
!Evidence of chronic liver disease including history of hepatitis, hepatitis B, or 
hepatitis C.
!History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of screening.
!Screening supi[INVESTIGATOR_205722] 12-lead ECG demonstrating QTcF interval >450 ms or a 
QRS interval >120 ms.
!Screening seated SBP ≥140 mmHg or DBP ≥90 mmHg, following ≥[ADDRESS_625581].
!Use of chronic prescription medications within 7 days or 5 half-lives (whichever is 
longer) before Day 1, or for prohibited medications, use within the required 
washout/restriction period in the protocol.
Additional Exclusion Criteria for Groups 2-4 Only (Mild, Moderate, and Severe HI)
!Hepatic carcinoma orhepatorenal syndrome orlimited predicted life expectancy 
(defined as <1 year).
!A diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular 
process that is documented by [CONTACT_9870], PE, liver biopsy, hepatic ultrasound, CT scan, or MRI.
!History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less 
than 4 weeks prior to screening.
!Signs of clinically active Grade 3 or 4 hepatic encephalopathy (ie, > Grade 2 Portal 
Systemic Encephalopathy score).
!Severe ascites and/or pleural effusion, except for those categorized in Group 4 who 
may be enrolled provided participant is medically stable, per the investigators’ 
medical judgment.
!Previously received a kidney, liver, or heart transplant.
!Screening supi[INVESTIGATOR_050] 12-lead ECG demonstrating a QTcF interval >470 ms or a QRS 
interval >120 ms.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge 1 3 At scree ni n g, Da y  - 1, or pre -d ose o n D a y  1, persiste nt se vere, u nc o ntr olle d 
h y perte nsi o n .
A L T or A S T > [ADDRESS_625582] u d y Ar ms a n d D ur ati o n: 
A t otal of a p pr o xi matel y  2 8- 3 2 partici pa nts wit h var y i n g de grees of he patic f u ncti o n will be 
a d mi nistere d a si n gle, oral  m g d ose of P F- 0 7 9 2 3 5 6 8 i n t he fe d state as s h o w n i n t he ta ble 
bel o w. 
He p atic F u ncti o n C ate g ories B ase d o n C hil d -P u g h Sc ore 
Gr o u p Descri pti o n C hil d -P u g h Sc ore N u m ber of P artici p a nts 
1 Wit h o ut he patic i m pair me nt N ot A p plica ble 8a
2 Mil d he patic i m pair me nt Class A ( 5 t o 6 p oi nts) 8
3 M o derate he patic i m pair me nt Class B ( 7 t o 9 p oi nts) 8
4 Se ver ehe patic i m pair me nt Class C ( 1 0 t o 1 5 p oi nts) 4- 8 b
a. A d diti o nal partici pa nts ma y be d ose d t o a ma xi m u m of 1 0 partici pa nts t o e ns ure mea n a ge ± 1 0 years a n d 
mea n b o d y wei g ht ± 1 5k g of t his gr o u p is ali g ne d wit h t he p o ole d a vera ge assesse d w he n a p pr o xi matel y 
≥ 7 5 % of partici pa nts are d ose d acr oss t he ot her 3gr o u p s. 
b. T he t otal n u m ber of partici pa nts e nr olle d t hat are classifie d as ha vi n g se vere HI will be a mi ni m u m of [ADDRESS_625583] u d y Gr o u ps 
Partici pa nts will be d ose d i n a sta ge d ma n ner as f oll o ws: 
Partici pa nts wit h m o derate HI ( Gr o u p 3) a n d se vere HI ( Gr o u p 4) will be e nr olle d 
first. 
Recr uit me nt of partici pa nts wit h mil d HI ( Gr o u p 2) will i nitiate w he n 
a p pr o xi matel y  5 0 % of t he partici pa nts i n Gr o u p 3 ha ve bee n d ose d. 
S p o ns or a p pr ov al is re q uire d bef ore pr ocee di n g wit h recr uit me nt of Gr o u p 2. 
A n a vera ge val ue f or a ge a n d wei g ht f or t he 3HI gr o u ps ( Gr o u ps 2- 4 ) will be 
deter mi ne d a n d partici pa nts wit h o ut HI ( Gr o u p 1) will be recr uite d t o matc h t he 
a vera ge de m o gra p hics (at a mi ni m u m, a ge a n d wei g ht, a n d as m uc h as practicall y  
p ossi ble ge n der) acr oss t he p o ole d Gr o u ps 2- 4. 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge 1 4 Recr uit me nt f or healt h y  partici pa nts i n Gr o u p 1 ( wit h o ut HI )m a y  start w he n 
a p pr o xi matel y  7 5 % of t otal partici pa nts acr oss Gr o u ps 2- 4 (ie, a p pr o xi matel y  1 5 
t o 1 8 partici pa nts) ha ve bee n d ose d. 
S p o ns or a p pr ov al is re q uire d bef ore pr ocee di n g wit h recr uit m e nt of Gr o u p 1. 
F or i n di vi d ual partici pa nts, t he t otal d urati o n of partici pati o n fr o m t he scree ni n g visit t o t he 
f oll o w -u p visit will ra n ge fr o m a p pr o xi matel y  5 wee ks ( mi ni m u m) t o a p pr o xi matel y 8wee ks 
( ma xi m u m). T he st u d y  c o nsists of a n i nitial scree ni n g peri o d of u p t o 2 8 da y s( w hile 
all o wi n g f or t he ret ur n a n d re vie w of all res ults, i ncl u di n g la b orat or y  tests) , a 6- d a y  i n patie nt 
sta y  at t he C R U w hic h i ncl u des a d mi nistrati o n of a si n gle oral d ose of P F -[ADDRESS_625584] u d y I nter ve nti o n(s) 
I nter ve nti o n N a me P F -0 7 9 2 3 5 6 8 
Ar m N a me 
( gr o u p of p artici p a nts recei vi n g a 
s pecific tre at me nt or n o tre at me nt) Gr o u p 1, Gr o u p 2, Gr o u p 3, Gr o u p 4 
U nit D ose Stre n gt h(s) m g 
R o ute of A d mi nistr ati o n Oral 
Use E x peri me ntal 
I M P or NI M P/ A x M P I M P 
A r m  Title Gr o u p [ADDRESS_625585] atistic al Met h o ds :
A sa m ple size of a p pr o xi matel y  2 8- 3 2 partici pa nts (a p pr o xi matel y  8 partici pa nts per Gr o u p s
1- 3, a n d 4 -8 partici pa nts i n Gr o u p 4 base do n recr uit me nt rate , wit h var y i n g de grees of 
he patic f u ncti o n i n eac h of t he 4gr o u ps) has bee n selecte d base d o n rec o m me n dati o n fr o m 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
C CI 
C CI 
C CI 
C CI 
C CI C CI 
C CI C CI 
C CI C CI 
C CI 
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 15the “FDA Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic 
Function: Study Design, Data Analysis, and Impact on Dosing and Labeling”.1Participants 
who discontinue from the study before completing all assessments may be replaced at the discretion of the investigator and sponsor.
The effect of varying degrees of HI on PK parameters will be assessed by [CONTACT_2164] 90% 
CI around the estimated difference between each of the Test (hepatic impaired) groups and the Reference (without hepatic impairment) group. A one-way ANOVA will be used to compare the natural log transformed PF-[ADDRESS_625586], as data permit, 
for each of the hepatic impairment groups (Test) to the group without hepatic impairment (Reference). Estimates of the adjusted mean differences (Test /Reference), and corresponding 90% CIs, will be obtained from the model. These will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.
All safety analyses will be performed on the safety population. AEs, ECGs, BP, pulse rate, 
and safety laboratory data will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate following Sponsor standards.
Ethical Considerations:A single dose of PF-[ADDRESS_625587] of varying degrees of HI on the PK of PF-07923568. Results from this study will be used in conjunction with collective safety, tolerability, efficacy, and PK/PD data from other PF-07923568 studies to develop dosing recommendations for the target patient populations with varying degrees of hepatic function.
1.2. Schema
090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 161.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the 
STUDY ASSESSMENTS AND PROCEDURES section of the protocol for detailed 
information on each procedure and assessment required for compliance with the protocol.
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA
table, in order to conduct evaluations or assessments required to protect the well-being of the participant.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 17Table 1. Study Schedule of Activities
Visit Identifier/Day
[list of abbreviations in Appendix 11 ]Screen
≤-[ADDRESS_625588] Dose -- 01234568101214 24 48 72 96 120 -- --
Informed consent & demography x
Outpatient visit x
Inpatient stay at CRU x ∀∀∀∀∀∀∀∀∀∀∀ ∀ ∀ ∀ ∀ x
COVID-19 assessmentb
Eligibility assessment x x x
Medical history x
Child-Pugh Classification scoring x
PE (height & weight at screening 
only)cxx xx
Breath alcohol & Urine drug test x x
Alcohol/tobacco & contraception usedxx xx x
(Update) Prior/concomitant 
treatmentsxx ∀∀∀∀∀∀∀∀∀∀∀ ∀ ∀ ∀ ∀ xx x
Single, supi[INVESTIGATOR_050] 12-lead ECGexx xexx x
Single, seated vital signs (BP, pulse 
rate)exx xexx x
AE monitoring (non-serious & SAEs) x ∀ ∀∀∀∀∀∀∀∀∀∀∀ ∀ ∀ ∀ ∀ xx x
Standard meals/optional snacksfxfxx x x x x x x x
Studyintervention administrationgx
Blood & Urine for clinical laboratory 
testshxxjxx
Serology for FSH (all females), HIV, 
HBsAg, HCVAb/RNAx
Serum pregnancy test (all females) x
Urine pregnancy test (WOCBP only)ix xx
Blood for PK sampling for 
PF-07923568 and Blood:Plasmaxjxx x xxkxx xkxxxx x x
Retained Research Sample for 
Genetics (Prep D1)lxj090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 18Table 1. Study Schedule of Activities
Visit Identifier/Day
[list of abbreviations in Appendix 11 ]Screen
≤-[ADDRESS_625589] Dose -- 01234568101214 24 48 72 96 120 -- --
Retained Research Sample for 
Biomarkers (Prep B2)mxj
a. Follow-up visit to be performed as telephone contact [CONTACT_486820] 28 to 35 days (ie, Day 29-36) from admin istration of study intervention. A clinic visit 
may be performed in place of telephone contact, if deemed necessary by [CONTACT_093], eg, for follow-up of abnormal laborato ry tests and/or open AEs.
b. Assessment of risk for, symptoms of or testing for COVID-19 may be performed at screening, admission to the CRU, and/or at ot her times during the study at investigator 
discretion and according to local site policies.
c. Complete PE at screening; at all other time points limited PE, at investigator discretion (see Section 8.3.1 ).
d. In confirmation of appropriate contraception use only.
e. If done around the time of a blood draw, ECG and vital sign assessments (BP and pulse rate) should be collected before the bl ood draw. ECG and vital signs on Day [ADDRESS_625590] be done before collection of the pre-dose blood samples. If an IV catheter is utilized for blood sample collections , ECGs and vital sign assessments (BP and 
pulse rate) should be collected before insertion of the catheter.
f. Meals/snacks to be served at clock times matching approximately 0H, 4H, 6H (optional snack), 10H, and 14H (optional snack) re lative to dosing on Day 1, while inpatient. 
Meals/snacks on Day -[ADDRESS_625591] prior to collection of the pre-dose PK sample o n Day 1 (see Section 5.3.2 ).
g. Dosing to occur with standard morning meal provided approximately [ADDRESS_625592] be reviewed and deemed acceptable (ie, negative) to continue participation in the study.
j. Samples at 0H on Day [ADDRESS_625593] be collected pre-dose.k. Whole blood aliquot (approximately 0.15 mL) will be collected from PK samples for in vivo blood:plasma ratio assessment.l. Prep D1 Retained Research Samples for Genetics: If not collected on the designated collection day, collect at the next availa ble time point when biospecimens are being 
collected in conjunction with a participant visit.
m. Prep B2 Retained Research Samples for Biomarkers: If not collected on the designated collection day, collect at the next avai lable time point when biospecimens are being 
collected in conjunction with a participant visit.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge 1 9 2. I N T R O D U C TI O N 
P F - 0 7 9 2 3 5 6 8 (sis u nat o vir) is bei n g de vel o pe d t o act as a hi g hl y  p ote nt, selecti ve, orall y 
a vaila ble a ge nt t o treat a n d pre ve nt R S V i nfecti o n. P F - [ADDRESS_625594] ill ness. 3H o we ve r, i n i nfa nts, y o u n g c hil dre n, t he 
i m m u n oc o m pr o mise d ,a n d t he el derl y, it ca n ca use seri o us L R TI .4I n fa nts < [ADDRESS_625595] ris k of se vere R S V i nfecti o n w hic h ca n lea d t o h os pi[INVESTIGATOR_1314] o n, I C U 
a d missi o n ,a n d e ve n deat h .5
T he c urre nt ma na ge me nt of R S V i nfecti o n i ncl u des a c o m bi nati o n of pre ve ntati ve a n d 
li mite d treat me nt meas ures, pri maril y  c o nsisti n g of s u p p orti ve care. Ri ba viri n, a n ucle osi de 
a nal o g ue, is c urre n tl y  t he o nl y  lice nse d a nti viral f or t he treat me nt of R S V i n c hil dre n 
( Viraz ole ®). 6T here is n o a p pr o ve d a nti viral f or t he treat me nt of R S V i n ot her a ge gr o u p s. 
M ost c urre nt g ui deli nes ma ke eit her n o rec o m me n dati o n or d o n ot rec o m me n d r o uti ne use of 
ri ba viri n d ue t o its wea k a nti viral ca pacit y , i n here nt t o xicit y  a n d terat o ge nic p ote ntial .7T h us, 
a place b o -c o ntr olle d desi g n is c o nsi dere d a p pr o priate f or trials of ne w a nti viral a ge nts f or t he 
treat me nt of R S V. Pali viz u ma b ( S y na gis ®) is a pr o p h y lactic m o n ocl o nal a nti b o d y  t hat has 
bee n s h o w n t o pr otect i nfa nts a gai nst R S V disease a n d is use d i n s pecifie d hi g h ris k i nfa nt 
gr o u ps. Des pi[INVESTIGATOR_040] t he a vaila bilit y  of t hese a ge nts, t heir li mite d use mea ns t hat treat me nt of 
R S V i nfecti o n re mai ns a n area of u n met nee d. 
P F - [ADDRESS_625596] u dies, pr o vi de a str o n g rati o nale f or t he cli nical de vel o p me nt of 
P F -0 7 9 2 3 5 6 8. 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
C CI C CI 
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_625597] u dies ,P F -0 7 9 2 3 5 6 8 s h o we d sl o w oral a bs or pti o n, m o derate- hi g h C L, hi g h 
v ol u me of distri b uti o n, a n d oral bi oa vaila bilit y  of 4 6 %, 4 2 -1 3 2 %, a n d 4 4 % i n m o use, rat, a n d 
d o g, res pecti vel y. 
Plas ma pr otei n bi n di n g of P F - 0 7 9 2 3 5 6 8 was l o w t o m o derate acr oss s pecies, wit h a vera ge 
fracti o n u n b o u n d of 6 7 %, 3 8 %, 5 2 %, 2 7 %, a n d 4 8 % i n h u ma n, m o use, rat, d o g ,a n d g ui nea 
pi g, res pecti vel y. Re peat d osi n g st u dies i n t he rat s h o w t hat e xte nsi ve distri b uti o n of 
P F - [ADDRESS_625598] is greater 
t ha n d ose pr o p orti o nal fr o m 5 0 m g/ k g t o 1 5 0 m g/ k g. 
C o nsiste nt wit h t he res ults of t he mi daz ola m D DI  st u d y  ( C 5 2 4 1 0 0 4), i n vitr o st u dies i n dicate 
t hat C Y P [ADDRESS_625599] u dies i n dicate a D DI ris k e xists f or O A T P 1 B 1/ [ADDRESS_625600] u dies i n dicate t here is a ris k of i n hi biti o n of C Y Ps 1 A 2, 2 B 6, 2 C 9, 
2 C 1 9, a n d 3 A 4. T he D DI wit h C Y Ps 1 A 2, 2 C 9, a n d 2 C 1 9 is pre dicte d t o be mi ni mal 
( pre dicte d less t ha n 2 5 % i ncrease i n A U C of a se nsiti ve s u bstrate) a n d D DI wi t h C Y P [ADDRESS_625601] u d y  c o n d ucte d wit h sis u nat o vir (  a n d 
as a se nsiti ve pr o be s u bstrate ( C 5 2 4 1 0 0 4) i n dicate t hat sis u nat o vir is   
I n vitr o st u dies i n dicate t hat sis u nat o vir is a P - g p s u bstrate; t heref ore, c o -a d mi nistrati o n of 
i n hi bit ors f or t he tra ns p orter ( P -g p) ma y  res ult i n i ncrease d e x p os ure t o sis u nat o vir 
(a p pr o xi matel y  2- f ol d). A cli nical D DI st u d y ( C 5 2 4 1 0 0 4) i n dicate d t hat  
 c oa d mi nistrati o n pr o d uce d a n a p pr o xi matel y   i n 
e x p os ure t o sis u nat o vir. 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
C CI C CI 
C CI C CI 
C CI 
C CI 
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 21The major metabolites produced in all species a ppeared to be h ydroxylated metabolites 
although some Phase 2 metabolites were also detected in all species. The metabolite profile in the rat, mouse, dog, guinea pig, and human were similar with the exception of M4, an apparent double hydroxylation only apparent in human at low levels.
Further details of the nonclinical PK and metabolism program are included in the IB.2.2.3. Nonclinical Safety
In the repeat dose toxicity studies in adult (up to 28 days) and neonatal/juvenile rats and 
dogs, the MTDs were defined by [CONTACT_486821]. In dogs, there was dose-related incidence of emesis and liquid feces at ≥15 mg/kg/day. The key target organ for 
toxicity in adult animals was the hepatobiliary system, which included both degenerative and inflammatory changes in bile duct, in rats ( ≥60 mg/kg/day) and dogs ( ≥45 mg/kg/day). In 
dogs, the hepatobiliary findings correlated with elevated plasma levels of ALP, ALT, and GGT. In addition, the findings observed only in rats were in kidney (degeneration/regeneration of medullary tubules) at ≥120 mg/kg/day, lung (vascular 
degeneration/necrosis) at 240 mg/kg/day (non-tolerated dose), and trachea (epi[INVESTIGATOR_486808] [predominantly in females]) at 120 mg/kg/day in 14 and/or 28-day studies. In the 28-day dog repeat dose toxicity study, the NOAEL was 15 mg/kg/day corresponding to C
maxof 729 ng/mL and AUC tauof 9510 ng.h/mL. In the 28-day 
rat repeat dose toxicity study, the NOAEL was 60 mg/kg/day corresponding to C maxof 322 
ng/mL and AUC tauof 4725 ng.h/mL.
In the embryo-fetal toxicity studies in rat (GD6-17) and rabbit (GD6-18), there were no 
effects on pregnancy or embryo-fetal development. In rat, the NOAEL for maternal toxicity was 45 mg/kg/day based on the transient initial body weight loss followed by [CONTACT_2715]-related decreased body weight gain at ≥45 mg/kg/day. The NOAEL for embryo-fetal toxicity in rat 
was 60 mg/kg/day, corresponding to systemic maternal exposure (AUC
24) of 9830 ng.h/mL 
on Day 15 of gestation. In rabbit, maternal toxicity was limited to lower body weight gain and food intake at 45 mg/kg/day. The NOAEL for embryo-fetal development in rabbit was 45 mg/kg/day, corresponding to a systemic maternal exposure (AUC
24) of 220 ng.h/mL on 
Day 16 of gestation.
Further details of the nonclinical toxicology program are included in the IB.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 222.2.4. Clinical Overview
Table 2. Completed PF-07923568 Studies
Study Number
(Status)Study Type/Key 
Design FeaturesStudy Population Dose, Dosing 
RegimenFormulation Used
C5241001-
previously 
REVC001a
(completed)Phase 1, 
randomised, 
double-blind, placebo-controlled, safety, tolerability, PK, food-effect of single ascending 
dose (SAD) and 
multiple ascending dose (MAD)Healthy participants Dose range: 10 mg –
525 mg (SAD); 
36 participants
Dose range: 175 mg 
– 350 mg; BID (MAD), food effect; 24 participantsLiquid Formulation
DIC
C5241002-previously REVC002(completed)Phase 2a, 
randomised, double-blind, placebo-controlledHealthy participants 
inoculated with RSV CV200 mg or 350 mg
BID for a total 10 doses; 66 participantsDIC
C5241004-
previously REVC004(completed)Phase 1, adaptive, 
part-randomised, part open-label, drug interactions, safetyand tolerabilityHealthy participants 200 mg; BID; 
62 participantsDIC
C5241005-
previously 
REVC005
(completed)Phase 1, open-label, 
single-dose, PK, 
safety, and 
tolerabilityHealthy participants 200 mg, 4 single 
doses total; 9 participants
1 ×: DIC (fed)
1 ×: DPB (fed)1 ×: DPB dispersed 
in H
2O (fed)
1 ×: DPB dispersed 
in H 2O (fasted)
[wash-out: 3 days between each of the 4 dosing days]DIC
DPB
a. A total of 8 participants received the liquid dosage formulation of PF-07923568 in a solution, at a 
concentration of 5 mg/mL, containing hydroxypropyl- β-cyclodextrin (HBP cyclodextrin), Lycasin, 
flavoring agent (strawberry) benzoic acid and water, and 68 subjects received DIC in the study.
Abbreviations: BID = twice-daily dosing; DIC = PF-07923568 drug in capsule; DPB = PF-07923568 dry 
powder blend; MAD = multiple ascending dose; PK = pharmacokinetic; RSV = respi[INVESTIGATOR_4345]; RSV CV = RSV challenge virus; SAD = single ascending dose.
A total of [ADDRESS_625602] received PF-07923568 in 4 completed clinical 
studies (C5241001, C5241002, C5241004, and C5241005) investigating the PK profile, effects of food on PK, effects of formulation on PK (C5241001, C5241005), DDIs (C5241004), and the efficacy in an RSV Viral Challenge Study (C5241002) at doses ranging 090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 23from [ADDRESS_625603] commonly reported treatment-related TEAEs were in the GI disorders SOC; nausea, diarrhea, and abdominal pain. These TEAEs have been mild to moderate in intensity and resolved without sequelae. Most events attributed to IMP involved the GI tract with nausea, diarrhea, and abdominal pain/discomfort/distension being the most common and occurring more commonly with the 350 mg dose of PF-07923568 than with the 200 mg PF-07923568 dose, where the number of participants reporting these events were lower and similar to those on placebo. In children, PF-07923568 is required to be suspended in a solution to enable oral administration, there has been evidence of poor tolerability when PF-07923568 was suspended in water as a singledose of 2.0 mg/kg in children aged 6-[ADDRESS_625604] been no SAEs attributable to PF-07923568 and no 
deaths in the clinical studies.
In adults, under both fasting and fed conditions, PF-07923568 is slowly absorbed reaching 
maximum plasma concentrations (t
max) at 5-6 hours (hrs) with a relatively moderate 
clearance, resulting in a half-life of 7-10 hrs in healthy participants. Dosing to steady state resulted in steady state concentrations being reached after approximately 2 days of dosing resulting in 2-4 fold accumulation of exposure. AUC and C
maxvalues increased in a greater 
than dose proportional manner across single and multiple dose studies. Following 5 days of dosing, the variability in PK parameters was high, with % CV ranging from 67.4-84% for C
maxand 71.9-144% for AUC 12.
The effect of food on the single dose PK was assessed for the DIC formulation and DPB 
formulation dispersed in water. For the DIC the extent of systemic exposure to PF-07923568(geometric mean AUC
infunder fed and fasted conditions) was 357 and 221 ng.h/mL,
respectively, with the between-subject variability being lower under fed conditions (CV 
64.1% compared with 198%). The ratio of fed/fasted was 218% (90% CI 94.2 - 502%) for 
Cmaxand 162% (90% CI 83.0 – 316%) for AUC 0-inf. It should be noted that the DIC fasted 
results from C5241001 were lower than typi[INVESTIGATOR_486809] 200 mg administered under fasting conditions resulting in an artificially higher ratio of fed/fasted in this study. For the DPB dispersed in water the extent of systemic exposure to PF-07923568(geometric mean AUC
inf) under fed and fasted conditions was 371 and 337 ng.h/mL,
respectively, with the between-subject variability being slightly lower under fasted conditions (CV 49.0% compared with 61.6%). The ratio of fed/fasted was 107.7% (90% CI 78.0 – 148.8%) for C
maxand 110.0% (90% CI 85.6 – 141.4%) for AUC inf. 
Clinical DDI Study C5241004 demonstrated that the disposition of PF-07923568 is expected 
to be affected by [CONTACT_486822]3A4. Furthermore, 090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 24PF-07923568 was demonstrated to be a moderate inhibitor of CYP3A4, so dose adjustments 
for compounds that are sensitive substrates for CYP3A4 may need to be considered.
In an RSV challenge study, PF-07923568 treatment resulted in a statistically significant 
reduction in AUC of RSV viral load compared with placebo; 55.25% (p=0.007) and 63.05% (p=0.002) for the 200 mg and 350 mg PF-07923568 dose groups, respectively (dosed every 12 hrs [Q12H] for 5 days). Results for the AUC of total symptom score were consistent with the viral load AUC. Geometric mean AUCs of total symptom score were 195.56, 30.79,and 31.76 hrs for placebo, 200 mg PF-07923568 and 350 mg PF-07923568, respectively. The reduction in AUCs of total symptom score compared with placebo was statistically significant for both PF-07923568 treatment groups; p=0.009 (70.84%) and p=0.002 (74.42%), (Wilcoxon Rank-Sum test) for the 200 mg and 350 mg PF-07923568 dose groups, respectively.
More detailed information about results of clinical studies for PF-07923568 may be found in 
the IB.
2.3. Benefit/Risk Assessment
PF-[ADDRESS_625605] been identified; postulated risks based on nonclinical studies are summarized in Section 2.2.[ADDRESS_625606], intensive, inpatient monitoring of the participants following administration of multiple oral doses of the study intervention.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of sisunatovir may be found in the IB, which is the SRSD for this study.
2.3.1. Risk Assessment
Potential Risk 
of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Study Intervention PF-[ADDRESS_625607] of both rats ( ≥60 mg/kg/day) and dogs 
(≥45 mg/kg/day) in studies of up to [ADDRESS_625608] monitoring including 
laboratory (ie, transaminases, ALP, GGT) and AE monitoring.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 25Potential Risk 
of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Gastrointestinal 
effectsTransient dose-related incidence of emesis and 
liquid feces in dogs at doses ≥15 mg/kg/day in 
studies up to 28 days. Additionally, inflammation in the duodenum, gall bladder, and liver at 45 mg/kg/day noted in 28-day dog study.
In previous clinical studies sisunatovir has been 
associated with mild GI AEs in fasted state.As this is an investigational agent, there 
is some risk that is mitigated by [CONTACT_486823], etc. Participants will be closely evaluated in an inpatient setting to monitor for GI AEs. If needed, palliative alleviating measures such as antiemetics may be provided.
Renal effects Degeneration/regeneration of medullary tubules 
was noted in rats at ≥120 mg/kg/day in studies 
of up to 28 days; considered non-adverse based on lack of clinical pathology changes.Standard monitoring including 
laboratory and AE monitoring.
Cardiovascular effectsMyocardial degeneration and necrosis were
noted at 240 mg/kg/day (non-tolerated dose) in 
a 14-day rat study.
No similar effect in rats at 120 mg/kg/day in 
the 28-day study, or in dogs at any dose, for [ADDRESS_625609]-in-human (FIH) study (C5241001) 
showed no adverse clinically significant 
changes in safety laboratory parameters (including troponin), ECGs, and VS.Monitoring will include VS, including 
heart rate and ECG assessments.
PulmonaryeffectsVascular degeneration/necrosis in lung at 240 
mg/kg/day and epi[INVESTIGATOR_59460]/necrosis in trachea at 120 mg/kg/day in 14-day rat study.
No similar effect in rats at 120 mg/kg/day in 
the 28-day study, or in dogs at any dose, for 14 
or 28 days.
Phase 1 FIH study (C5241001) showed no 
adverse clinically significant changes in safety laboratory parameters (including troponin), ECGs, and VS.There will be standard safety 
monitoring including VS and AEs. 
Thymus effects Lymphoid atrophy and decreased thymus 
weight and reduced size of thymus in both rats 
(≥120 mg/kg/day) and dogs ≥15 mg/kg/day) in 
studies of up to [ADDRESS_625610] monitoring including 
laboratory (ie, complete blood count 
with differential) and AE monitoring. Single dose regimen should further limit this potential risk.
Other
Risk of COVID-19 exposure during studyDuring the pandemic, study participants could 
be exposed to the SARS-CoV-2 virus during study participation. This could lead to increased health risk for this participant and others in the study.Assessment of risk for, symptoms of,
or testing for COVID-19 may be performed at screening, admission to the CRU, and/or at other times during the study at investigator discretion and according to local site policies.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 262.3.2. Benefit Assessment
A single dose of PF-[ADDRESS_625611] of varying degrees of hepatic impairment on the PK of PF-07923568 to support further clinical development of PF-07923568 as a potential treatment of RSV. Results from this study will be used in conjunction with collective safety, tolerability, efficacy, and PK/PD data from other PF-07923568 studies to develop dosing recommendations for the target patient population with varying degrees of hepatic function.
2.3.3. Overall Benefit/Risk Conclusion
PF-07923568 is not expected to provide any clinical benefit to healthy participants in this 
study.
Based on the profile of PF-07923568 observed in nonclinical and clinical studies to date, and 
taking into account the measures to minimize risk to study participants, the potential risk to the participants in this study is deemed to be minimal and is justified by [CONTACT_486824]-07923568in the future.
3. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary: Primary:
!To compare the PK of PF-07923568 following administration 
of a single oral dose in adult participants with varying degrees of HI relative to age- and body weight-matched participants without HI.!Plasma: C
max, AUC lastor AUC inf*, as data 
permit.
Secondary: Secondary:
!To evaluate the safety and tolerability of a single oral dose of 
PF-07923568 when administered to adult participants with varying degrees of HI and in age- and body weight-matched participants without HI.!Assessment of TEAEs, clinical laboratory 
abnormalities, VS, ECG parameters.
Tertiary/Exploratory: Tertiary/Exploratory:
!To compare additional PK parameters of PF-07923568 
following administration of a single oral dose in adult participants with varying degrees of HI and in age- and body weight-matched participants without HI.!Plasma: CL/F, V
z/F, T maxand t 1/2as data permit.
* AUC lastwill be treated as primary endpoints if data do not permit robust estimation of AUC inf, otherwise they will be 
treated as tertiary endpoints.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_625612] 
of var y i n g de grees of he patic f u ncti o n o n t he plas ma P K of P F - 0 7 9 2 3 5 6 8 after a si n gle, oral 
m g d ose a d mi nistere d i n t he fe d state (sta n dar d brea kfast) . Safet y a n d t olera bilit y  will be 
e val uate d t hr o u g h o ut t he st u d y . A t otal of a p pr o xi matel y  2 8- 3 2 partici pa nts wit h var y i n g 
de grees of he patic f u ncti o n will be a d mi nistere d as a si n gle, oral   m g d ose of 
P F -0 7 9 2 3 5 6 8 i n t he fe d state as s h o w n i n Ta ble 3. 
T a ble 3. He p atic F u ncti o n C ate g ories B ase d o n C hil d -P u g h Sc ore 
Gr o u p Descri pti o n C hil d -P u g h Sc ore N u m ber of 
P artici p a nts 
1  Wit h o ut HI N ot A p plica ble 8a
2 Mil d HI Class A ( 5 t o 6 p oi nts) 8
3 M o derate HI Class B ( 7 t o 9 p oi nts) 8
4 Se vere HI Class C ( 1 0 t o 1 5 p oi nts) 4- 8 b
a. A d diti o nal partici pa nts ma y be d ose d t o a ma xi m u m of 1 0 partici pa nts t o e ns ure mea n a ge ± 1 0 years a n d 
mea n b o d y wei g ht ± 1 5 k g of t his gr o u p is ali g ne d wit h t he p o ole d a vera ge assesse d w he n a p pr o xi matel y 
≥ 7 5 % of partici pa nts are d ose d acr oss t he ot her 3gr o u p s. 
b. T he t otal n u m ber of partici pa nts e nr olle d t hat are classifie d as ha vi n g se vere HI will be a mi ni m u m of [ADDRESS_625613] u d y Gr o u ps 
Partici pa nts will be d ose d i n a sta ge d ma n ner as f oll o ws: 
Partici pa nts wit h m o derate HI ( Gr o u p 3) a n d se vere HI ( Gr o u p 4) will be e nr olle d 
first. 
Recr uit me nt of partici pa nts wit h mil d HI  ( Gr o u p 2) will i nitiate w he n 
a p pr o xi matel y  5 0 % of t he partici pa nts i n Gr o u p 3 ha ve bee n d ose d .
S p o ns or a p pr ov al is re q uire d bef ore pr ocee di n g wit h recr uit me nt of Gr o u p 2. 
A n a vera ge val ue f or a ge a n d wei g ht f or t he 3 HI gr o u ps ( Gr o u ps 2-4) will be 
deter mi ne d a n d partici pa nts wit h o ut HI  ( Gr o u p 1) will be recr uite d t o matc h t he 
a vera ge de m o gra p hics (at a mi ni m u m, a ge a n d wei g ht, a n d as m uc h as practicall y  
p ossi ble ge n der) acr oss t he p o ole d Gr o u ps 2- 4. 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
C CI 
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 28!Recruitment for healthy participants in Group 1 (without HI) may start when 
approximately 75% of total participants across Groups 2-4 (ie, approximately 15to 18 participants) have been dosed.
!Sponsor approval is required before proceeding with recruitment of Group 1.
Participants who prematurely discontinue before completing all assessments may be 
replaced, at the discretion of the investigator and sponsor study team.
The overall study design is presented as a schematic in Section 1.2 and below. For individual 
participants, the total duration of participation from the screening visit to the follow-up visit will range from approximately 5 weeks (minimum) to approximately 8 weeks (maximum).The study consists of an initial screening period of up to 28 days (while allowing for the return and review of all results, including laboratory tests), a 6-day inpatient stay at the CRU which includes administration of a single oral dose of PF-07923568, and a follow-up contact [CONTACT_110278] 28-[ADDRESS_625614] of hepatic impairment on human PK 
for compounds cleared in a similar manner to PF-07923568 (CYP3A-mediated metabolism), 
impaired hepatic function is generally associated with increased drug exposures in plasma 
(internal data and data cited in University of Washington Drug Interaction Database). 
090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_625615] u d y  will e nr oll partici pa nts wit h va r y i n g de grees of he patic i m pair me nt, a n d partici pa nts 
wit h o ut he patic i m pair me nt ( matc he d f or a ge as well as b o d y wei g ht a n d ge n der ,as m uc h as 
practicall y p ossi ble) i n or der t o all o w a r o b ust assess me nt of P K acr oss t he e ntire s pectr u m of 
he patic f u ncti o n .
N o ncli nical st u dies i n dicate t hat t he cleara nce of sis u nat o vir f oll o wi n g oral a d mi nistrati o n t o 
rats is pre d o mi na ntl y  he patic. A rat bile -d uct ca n n ulate d st u d y  s h o we d ne gli gi ble re nal 
e xcreti o n ( St u d y  P P N 7 0 - 0 5 8. 0 4). F urt her m ore, a n A D M E (a bs or pti o n, dist ri b uti o n, 
meta b olis m, a n d e xcreti o n) st u d y  i n male S pra g ue -Da wle y  rats t hat recei ve d a si n gle oral 
a d mi nistrati o n of [ 1 4 C] -sis u nat o vir s h o we d t hat e xcreti o n was pre d o mi na ntl y via t he fecal 
r o ute a n d uri ne acc o u nte d f or < 4 % of t he d ose ( St u d y  R V L/ 0 1). It is a ntici pate d t hat re nal 
e xcreti o n will be si milarl y  l o w i n h u ma ns .
Gi ve n t he eli mi nati o n of sis u nat o vir via he patic e nz y mes wit h mi ni mal c o ntri b uti o n b y  re nal 
eli mi nati o n, it is e x pecte d t hat HI c o ul d ha ve a n effect o n t he cleara nce of sis u nat o vir. 
F oll o wi n g a d mi nistrati o n of si n gle d oses of P F - [ADDRESS_625616] -d ose , w hic h is e x pecte d t o 
a de q uatel y c haracterize t he eli mi nati o n p hase of t he plas ma c o nce ntrati o n- ti me pr ofile i n t he 
c o h orts wit h var y i n g de grees of HI .T he pr otei n bi n di n g of P F - 0 7 9 2 3 5 6 8 i n h u ma ns is 3 3 %, 
res ulti n g i n a hi g h f u of 6 7 %. 
A vaila ble P K data wit h P F - [ADDRESS_625617] t he c o n diti o ns f or a ntici pate d use of 
P F -0 7 9 2 3 5 6 8 i n f ut ure trials. 
I n ge neral, partici pa nts wit h n or mal he patic f u ncti o n ( Gr o u p 1) will a bstai n fr o m 
c o nc o mita nt treat me nts, e xce pt f or t he treat me nt of A Es . Use of selecte d li mite d prescri pti o n 
a n d n o n -prescri pti o n me dicati o ns ma y  be per mitte d (refer t o Secti o n 6. 9 f or details). 
Partici pa nts wit h i m paire d he patic f u ncti o n ( Gr o u ps 2- 4) are per mitte d t o be o n sta ble d oses 
of bac k gr o u n d me dicati o ns f or t he ma na ge me nt of t heir c o nc o mita nt me dical c o n diti o n(s) 
wit h s o me e xcl usi o ns ( see A p pe n di x 9 ). Acc or di n g t o t he D DI ris k assess me nt f or 
P F -[ADDRESS_625618] u d y . 
Si nce P F - 0 7 9 2 3 5 6 8 is a P -g p a n d C Y P 3 A 4 s u bstrate, str o n g a n d m o derate C Y P 3 A 4 
i n hi bit ors a n d str o n g P -g p i n hi bit ors are als o pr o hi bite d. L astl y, d ue t o ris k of M A T E 1 a n d 
O C T 1 i n hi biti o n, se nsiti ve s u bstrates of t hese tra ns p orters are pr o hi bite d. 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_625619] u d y  site 
pers o n nel, assess me nt of ris k f or, s y m pt o ms of or testi n g f or C O VI D -1 9 ma y  be perf or me d at 
scree ni n g, a d missi o n t o t he C R U ,a n d/ or at ot her ti mes d uri n g t he st u d y  at i n vesti gat or 
discreti o n a n d acc or di n g t o l ocal site p olicies. 
T he C hil d -P u g h Classificati o n (refer t o A p pe n di x 1 0) will be use d t o defi ne t he 3gr o u ps of 
partici pa nts wit h var y i n g de grees of HI . T his st u d y  will i ncl u de partici pa nts wit h mil d 
( C hil d - P u g h Class A, Gr o u p 2), m o derate ( C hil d -P u g h Class B, Gr o u p 3) , a n d se vere 
( C hil d -P u g h Class C, Gr o u p 4) HI as well as de m o gra p hic all ymatc he d c o ntr ol partici pa nts 
wit h o ut HI ( Gr o u p 1). All partici pa nts will be re q uire d t o pr o vi de t heir o w n c o nse nt t o 
partici pate i n t his st u d y , he nce partici pa nts wit h cli nicall y  acti ve Gra de [ADDRESS_625620] or y  of 
Gra de 3 or 4 e nce p hal o pat h y  b ut are c urre ntl y recei vi n g a n i nter ve nti o n (e g ,lact ul ose or 
lactit ol, al o ne or i n c o m bi nati o n wit h rifa xi mi n, a n d/ or ne o m y ci n) t o ma na ge t heir 
e nce p hal o pat h y-relate d si g ns a n d s y m pt o ms are e li gi ble pr o vi de d t he o n- treat me nt 
e nce p hal o pat h y gra di n g at t he scree ni n g visit is Gra de 2 or l o wer, t here b y per mitti n g t he m t o 
pr o vi de t heir o w n i nf or me d c o nse nt. Ac k n o wle d gi n g t he me dical state of t he p o p ulati o n 
e nr olle d, certai n eli gi bilit y  criteria f or partici pa nts wit h he patic i m pair me nt are disti nctl y  
differe nt, wit h n o s pecific e xcl usi o n of partici pa nts wit h He patitis B a n d He patitis C i n 
Gr o u ps 2- 4. 
4. 2. 1. C h oice of C o ntr ace pti o n/ B arrier Re q uire me nts 
H u ma n re pr o d ucti ve safet y  data are li mite d f or sis u nat o v ir, b ut t here is n o s us pi[INVESTIGATOR_37180] o n of 
h u ma n terat o ge nicit y base d o n t he i nte n de d p har mac ol o g y of t he c o m p o u n d. Theref ore t he 
use of a hi g hl y effecti ve met h o d of c o ntrace pti o n is re q uire d f or all fertile partici pa nts (see 
A p pe n di x 4). 
4. 2. 2. C ollecti o n of Ret ai ne d Rese arc h S a m ples 
Retai ne d Researc h Sa m ples will be c ollecte d a n d st ore d f or f urt her a nal ys es w hic h ma y , f or 
e xa m ple, pr o vi de greater u n dersta n di n g of t he st u d y  i nter ve nti o n. 
4. 3. J ustific ati o n f or D ose 
W hile t here is u ncertai nt y  of t he effects of HI o n t he e x p os ure of P F -[ADDRESS_625621] u dies wit h P F - 0 7 9 2 3 5 6 8 
(Secti o n 2. 2. 4 ) de m o nstrati n g t hat it is safe a n d well t olerate d. T he cli nical pr o gra m f or 
P F -0 7 9 2 3 5 6 8 has e val uate d d oses u p t o 3 5 0 m g t wice dail y ( BI D) f or 5 da ys t o date 
T he cli nical pr o gra m f o r P F - 0 7 9 2 3 5 6 8 has e val uate d d oses u p t o 3 5 0 m g t wice dail y ( BI D )
f or [ADDRESS_625622] u d y 
( C 5 2 4 1 0 0 2) as well as ot her P hase 1 st u dies c o n d ucte d t o date. H o we ver, u n der fasti n g 
c o n diti o ns a n i ncrease d i nci de nce of GI A Es , pri maril y  mil d a n d m o derate HI, were o bser ve d 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_625623] u d y  
(D P B i n ca ps ules) s h o we d mi ni mal f o o d effect acc o m pa nie d b y a decrease i n o bser ve d 
varia bilit y .Gi ve n t he a b o ve, it is a ntici pate d t hat wi t h a si n gl e m g d ose p ote ntial 
i ncreases i n plas ma e x p os ure i n partici pa nts wit h var y i n g de grees of he patic i m pair me nt i n 
t he c urre nt st u d y , if e nc o u ntere d, are n ot a ntici pate d t o p ose a n u n d ue safet y  ris k. 
4. 4. E n d of St u d y Defi niti o n 
T he e n d of t he st u d y is defi ne d as t he date of t he f oll o w - u p as s h o w n i n t he S o A f or t he last 
partici pa nt i n t he trial gl o ball y .
A partici pa nt is c o nsi dere d t o ha ve c o m plete d t he st u d y  if t he y  ha ve c o m plete d all p hases of 
t he st u d y , i ncl u di n g t he f oll o w -u p visit ( tele p h o ne c o ntact or o n site visit per in vesti gat or 
discreti o n )as s h o w n i n t he S o A .
5. S T U D Y P O P U L A TI O N 
T his st u d y  ca n f ulfill its o bjecti ves o nl y  if a p pr o priate partici pa nt s are e nr olle d , i ncl u di n g 
par tici pa nts acr oss di verse a n d re prese ntati ve racial a n d et h nic bac k gr o u n ds. Use of a 
prescree n i n g t o ol is utilize d f or st u d y recr uit me nt p ur p oses , it will i ncl u de c ollecti o n of 
i nf or mati o n t hat reflects t he e nr oll me nt of a di verse partici pa nt p o p ulati o n i ncl u di n g, w here 
per mitte d u n der l ocal re g ulati o ns, a ge, se x, a n d race, a n d et h nicit y . T he f oll o wi n g eli gi bilit y  
criteria are desi g ne d t o select partic i pa nt s f or w h o m partici pati o n i n t he st u d y  is c o nsi dere d 
a p pr o priate. All rele va nt me dical a n d n o n me dical c o n diti o ns s h o ul d be ta ke n i nt o 
c o nsi derati o n w he n deci di n g w het her a partic ular partici pa nt is s uita ble f or t his pr ot oc ol .
Pr os pecti ve a p pr o val of pr ot oc ol de viati o ns t o recr uit me nt a n d e nr oll me nt criteria ,als o 
k n o w n as pr ot oc ol wai vers or e xe m pti o ns, is n ot per mitte d .
5. 1. I ncl usi o n Criteri a 
Partici pa nts are eli gi ble t o be i ncl u de d i n t he st u d y o nl y if all of t he f oll o wi n g criteria a p pl y: 
5. 1. 1. P artici p a nts i n All Gr o u p s
A ge a n d Se x :
1. Male or fe male bet wee n t he a ges of 1 8 ( or t he mi ni m u m c o u ntr y -s pecific a ge of 
c o nse nt if > 1 8) a n d [ADDRESS_625624] u d y .Refer t o A p pe n di x 4 f or re pr o d ucti ve 
criteria f or male ( Secti o n 1 0. 4. 1 ) a n d fe male ( Secti o n 1 0. 4. 2 ) partici pa nts. 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 32Other Inclusion Criteria:
2. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, 
lifestyle considerations (as described in Section 5.3 ), and other study procedures.
3. BMI of 17.5 to 38.0 kg/m2, inclusive; and a total body weight >50 kg (110 lb), at the 
screening visit; with a single repeat assessment of total body weight (and hence BMI), on a separate day before Day -1 permitted to assess eligibility, if needed.
4. Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
5.1.2. Additional Inclusion Criteria for Group 1 Only (without HI)
1. At screening, no clinically relevant abnormalities identified by a detailed medical 
history, complete PE, including BP and pulse rate measurement, 12-lead ECG and clinical laboratory tests, as assessed by [CONTACT_374453].
2. At screening, participants must meet the demographic-matching criteria, including:
!A body weight that is within ±15 kg of the average of the pooled hepatic 
impairment groups (Groups 2-4), as provided by [CONTACT_456];
!An age that is within ±10 years of the average of the pooled hepatic impairment 
groups (Groups 2-4), as provided by [CONTACT_456];
!Attempts will be made to ensure that the male-to-female distribution in Group 1 is 
comparable to that in the pooled hepatic impairment groups (Groups 2-4).
3. No known or suspected hepatic impairment, and meet allthe following criteria at 
screening, as assessed by [CONTACT_374453], with a single repeat 
permitted to assess eligibility, if needed:
!ALT ≤ ULN;
!AST ≤ ULN;
!T bili ≤ ULN.
NOTE : Participants with a history of Gilbert syndrome (and hence elevated T bili) 
are eligible provided direct bilirubin level is ≤ULN plus ALT and AST are ≤ULN 
plus alkaline phosphatase, hemoglobin, and reticulocyte count are all ≤ULN.
!Albumin ≤ ULN;
!PT≤ ULN.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 335.1.3. Additional Inclusion Criteria for Groups 2-4 Only (Mild, Moderate, and Severe
HI)
1. Stable hepatic impairment that meets the criteria for Class A, B, or C of the
Child-Pugh classification (refer to Appendix 10 ) with no clinically significant change 
in disease status within the 28 days prior to the screening visit, as documented by [CONTACT_2299]’s recent medical history (eg, no worsening clinical signs of hepatic impairment, no worsening of T bili or PT by [CONTACT_726] 50%).
2. Stable concomitant medications for the management of individual participant’s 
medical history; on a case-by-case basis , with approval from the sponsor, participants 
receiving fluctuating concomitant medication/treatment may be considered if the 
underlying disease is under control.
5.2. Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
5.2.1. Participants in All Groups
Medical Conditions:
1. Any condition possibly affecting drug absorption (eg, prior bariatric surgery, 
gastrectomy, ileal resection).
NOTE: Participants who have undergone cholecystectomy and/or appendectomy are 
eligible for this study as long as the surgery occurred more than 6 months prior to screening.
2. At screening, a positive result for HIV antibodies, as assessed by [CONTACT_486825], with a single repeat permitted to assess eligibility, if needed.
3. History of surgery that would be expected to alter absorption, distribution, 
metabolism, or excretion properties of PF-07923568 (eg, status post portacaval shunt surgery).
NOTE: Participants with a trans-jugular intrahepatic portosystemic shunt are 
permitted provided that they meet the Child-Pugh criteria.
4. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg, contact [CONTACT_216478]) that may 
increase the risk of study participation or, in the investigator’s judgment, make the 
participant inappropriate for the study.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 34Prior/Concomitant Therapy
5. Use of specific prohibited prior/concomitant therapi[INVESTIGATOR_107058] 6.[ADDRESS_625625] (drug or 
vaccine) within 30 days (or as determined by [CONTACT_19970]) or [ADDRESS_625626] dose of study intervention used in this study (whichever is longer). Investigational products which are strong CYP3A inducers or time-dependent inhibitors are prohibited within 14 days plus 5 half-lives prior to the dose of study intervention.
Prior/Concurrent Clinical Study Experience:
6. Known prior participation (ie, received at least 1 dose of study intervention) in a 
study involving PF-07923568.
Diagnostic Assessments:
7. eGFR <60 mL/min/1.73m
2(calculated with the 2021 CKD-EPI [INVESTIGATOR_185572]-Scys combined 
equation, see Appendix 7 ), at the screening visit, as assessed by [CONTACT_486826], and confirmed by a single repeat test, if deemed necessary.
8. A positive urine drug test at screening or Day -1. However, participants in 
Groups 2-4, only , who have been medically prescribed medications, 
eg, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], cannabinoids, benzodiazepi[INVESTIGATOR_1651], methylphenidate (or similar), and 
report the use of these drugs to the investigator at the screening visit may be allowed to participate, after approval from the sponsor, and if in line with protocol specifications regarding prohibited medications (see Section 6.9 , Appendix 9 ).
NOTE : Repeat urine drug testing to assess study eligibility at screening or Day -[ADDRESS_625627], as assessed using kits approved 
by [CONTACT_3211]; for the screening test, a single repeat (which may be on a separate day)
before Day -[ADDRESS_625628] at screening 
and/or positive urine pregnancy test in WOCBP at Day -1.
11.If performed at investigator discretion, safety related laboratory tests collected on 
Day -1, upon review prior to dosing reflect the participant not to be in stable medical condition.
Other Exclusion Criteria:
12. Blood donation (excluding plasma donations) of approximately 1 pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_625629].090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 3513. History of sensitivity to heparin or heparin-induced thrombocytopenia, only if heparin 
is used to flush IV catheters used during serial blood collections.
14. Investigator site staff directly involved in the conduct of the study and their family 
members, site staff otherwise supervised by [CONTACT_093], and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
5.2.2. Additional Exclusion Criteria for Group 1 Only (without HI)
1. Evidence of chronic liver disease including history of hepatitis, hepatitis B, or 
hepatitis C or evidence of any of the following, as assessed by [CONTACT_486827], with a single repeat, permitted to assess eligibility, if needed:
!Hepatitis B virus, defined by [CONTACT_107077] B surface antigen (HBsAg);
NOTE: while notpart of the tests assessed in this study, a previously positive 
hepatitis B surface antibody result due to vaccination is permissible.
!Hepatitis C infection, defined by [CONTACT_486828].
2. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spi[INVESTIGATOR_107060] 3 ounces (90 mL) of wine.
3. Screening supi[INVESTIGATOR_205722] 12-lead ECG demonstrating QTcF interval >450 ms or a 
QRS interval >120 ms. If QTcF exceeds 450 ms, or QRS exceeds 120 ms, the ECG 
should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant’s eligibility.
4. Screening seated SBP ≥140 mmHg or DBP ≥90 mmHg, following ≥[ADDRESS_625630]. If SBP is ≥140 mmHg or DBP ≥90 mmHg, the BP assessment should be 
repeated 2 more times and the average of the 3 BP values should be used to determine eligibility.
5. Use of chronic prescription medications within 7 days or 5 half-lives (whichever is 
longer) prior to Day 1, or for prohibited medications, use within the required 
washout/restriction period provided in Appendix 9 .
NOTE: Use of selected, limited prescription and non-prescription medications may 
be permitted on a case-by-case basis after approval from the sponsor (refer to 
Section 6.9 for details).090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 365.2.3. Additional Exclusion Criteria for Groups 2-4 Only (Mild, Moderate, and Severe
HI)
1. Hepatic carcinoma orhepatorenal syndrome orlimited predicted life expectancy 
(defined as <1 year).
2. A diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular 
process that is documented by [CONTACT_9870], PE, liver biopsy, hepatic ultrasound, CT scan, or MRI.
3. History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less 
than 4 weeks prior to the screening visit.
4. Signs of clinically active Grade 3 or 4 hepatic encephalopathy (ie, >Grade 2 Portal 
Systemic Encephalopathy score; refer to Appendix 10 ).
5. Severe ascites and/or pleural effusion, except for those categorized in Group 4 who 
may be enrolled provided participant is medically stable, per the investigators’ medical judgment.
6. Previously received a kidney, liver, or heart transplant.7. Screening supi[INVESTIGATOR_050] 12-lead ECG demonstrating a QTcF interval >470 ms or a QRS 
interval >120 ms. If QTcF exceeds 470 ms, or QRS exceeds 120 ms, the ECG should 
be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine eligibility.
8. At screening, Day -1 or pre-dose on Day 1, persistent severe, uncontrolled 
hypertension as outlined below:
!Seated SBP ≥180 mmHg or DBP ≥105 mmHg after ≥[ADDRESS_625631], 
with a single repeat permitted to assess eligibility, if needed, at each of these 2 
visits; if done, the repeat assessment overrides initial results.
NOTE : For participants with SBP ≥160 and ≤179 mmHg orDBP ≥100 and 
≤104 mmHg at screening, the period between screening and Day 1 may be used to 
refine the doses of the agents used for management of BP with the aim of havingstable BP by [CONTACT_2006] -1.
!Day 1 : seated SBP ≥160 mmHg or DBP ≥100 mmHg after ≥[ADDRESS_625632], with a single repeat permitted to assess eligibility, if needed; if done, the 
repeat assessment overrides initial results.
9. ALT orAST >5x ULN on clinical laboratory tests at screening, as assessed by [CONTACT_486829], with a single repeat permitted to assess eligibility, if 
needed.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 375.3. Lifestyle Considerations
After confirmation of eligibility, participants will be instructed to maintain the guidelines 
described below for the duration of participation in the study.
5.3.1. Contraception
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant from the permitted list of contraception methods (see Appendix 4 ,Section 10.4.4 ) and will 
confirm that the participant has been instructed in its consistent and correct use. At time points indicated in SoA, the investigator or designee will inform the participant of the need to 
use highly effective contraception consistently and correctly and document the conversation and the participant’s affirmation in the participant’s chart. Participants need to affirm their consistent and correct use of at least [ADDRESS_625633] the participant to call immediately if the 
selected contraception method is discontinued and document the requirement to use an alternate protocol-specified method, including if the participant will no longer use abstinence as the selected contraception method, or if pregnancy is known or suspected in the participant or partner.
5.3.2. Meals and Dietary Restrictions
!Participants must abstain from all food and drink (except water) at least 4 hours prior 
to all fasting clinical laboratory evaluations and pre-dose PK sample (0.5 hrs prior to dosing) on Day 1.
!Water may be consumed as desired (ad libitum).
!While inpatient, all meals will be standardized as follows:
!On Day 1, following a fast of at least [ADDRESS_625634]. There will be no water restrictions prior to dosing.
!Standard morning meal, lunch, an optional afternoon snack, an evening meal, and 
an optional evening snack will be provided at a similar clock time to the clock time when these meals are provided relative to dosing on Day 1 while inpatient ie, approximately 0, 4, 6 (optional snack), 10, and 14 hrs (optional snack).
!The total daily nutritional composition should be approximately 
55% carbohydrate, 30% fat and 15% protein. The nutritional macronutrient 090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 38composition consumed by [CONTACT_107078], as much as 
practically possible.
!The daily caloric intake per participant should not exceed approximately 
3200 kcal.
!Participants will refrain from consuming red wine, grapefruit, or grapefruit-
related citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to Day 1 and until collection of the final PK blood sample.
!When a meal or snack is scheduled at the same time as an ECG and/or VS
assessments, the meal will be provided after the ECG and/or VS assessments arecompleted.
5.3.3. Caffeine, Alcohol, and Tobacco
!Participants will abstain from alcohol for ≥24 hrs prior to admission for inpatient stay 
(and for red wine abstain for at least 7 days prior to Day 1), plus have a negative breath alcohol test on Day 1 and continue abstaining from alcohol until collection of the final PK blood sample.
!Participants will undergo breath alcohol tests at timepoints indicated in the SoA, 
additional tests may be conducted at investigator discretion
!Consumption of caffeinated drinks and tobacco (or nicotine containing products) is 
permitted during participation in the study; however, there may be a need for brief interruption while at the site, depending on local site policy.
In addition:
!Participants must abstain from caffeine-containing products for a minimum of 2 hrs 
prior to all vital signs and ECG measurements conducted throughout study participation (from screening to the final follow-up).
!Smoking may not be permitted when it would interfere with the timing of scheduled 
study procedures. In addition, participants must abstain from use of tobacco- or nicotine-containing products: for a minimum of 2 hrs prior to all vital signs and ECG measurements, for a minimum of 2 hrs prior to and following administration of study intervention.
5.3.4. Activity
!Participants will notbe permitted to engage in physically strenuous exercise 
(eg, heavy lifting, weight training, calisthenics, and aerobics) within 48 hrs before 
each blood sample collection for clinical laboratory tests while participating in the study; physical activity at an individual participant’s normal pace is permitted.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge 3 9 I n or der t o sta n dar dize t he c o n diti o ns o n P K sa m pli n g da y s, all partici pa nts will be 
re q uire d t o refrai n fr o m l y i n g  d o w n (e xce pt if re q uire d f or st u d y  pr oce d ures, 
e g, E C G), eati n g, a n d dri n ki n g be vera ges ot her t ha n water d uri n g t he first [ADDRESS_625635] u d y  (scree n fail ure) ma y  n ot be 
rescree ne d. 
I n cases w here rescree ni n g is per mitte d , all scree ni n g pr oce d ures m ust be re peate d a n d t he 
partici pa nt assi g ne d a ne w 8- di git S SI D n u m ber. Partici pa nts m ust be dee me d t o meet all t he 
eli gi bilit y  criteria u n der t he ne w 8 di git S SI D bef ore pr o gressi n g t o Da y 1. Rec o nse nt is 
re q uire d. 
6. S T U D Y I N T E R V E N TI O N( S) A N D C O N C O MI T A N T T H E R A P Y 
St u d y  i nter ve nti o ns are all pres pecifie d i n vesti gati o nal pr o d ucts, me dical de vices, a n d ot her 
i nter ve nti o ns (e g, s ur gical a n d be ha vi oral) i nte n de d t o be a d mi nistere d t o t he st u d y  
partici pa nts d uri n g t he st u d y  c o n d uct. 
F or t he p ur p oses of t his pr ot oc ol, st u d y  i nter ve nti o n refers t o P F - [ADDRESS_625636] u d y I nter ve nti o n(s) A d mi nistere d 
St u d y I nter ve nti o n(s) 
I nter ve nti o n N a me P F - 0 7 9 2 3 5 6 8 
Ar m N a me 
( gr o u p of p artici p a nts recei vi n g a 
s pecific tre at me nt or n o tre at me nt) Gr o u p 1, Gr o u p 2, Gr o u p 3, Gr o u p [ADDRESS_625637] u g 
D ose F or m ul ati o n Ca ps ule 
U nit D ose Stre n gt h(s) m g 
D os a ge Le vel(s) m g ,si n gle d ose 
R o ute of A d mi nistr ati o n Oral 
Use E x peri me ntal 
I M P or NI M P/ A x M P I M P 
S o urci n g Pr o vi de d ce ntrall y b y t he s p o ns or . Refer t o t he I M P .0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
C CI 
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_625638] u d y I nter ve nti o n(s) 
P ac k a gi n g a n d L a beli n g St u d y i nter ve nti o n will be pr o vi de d as o pe n -la bel s u p pl y i n b ul k b ottles 
al o n g wit h i n di vi d ual d ose c o ntai ners, as necessar y, f or u nit d osi n g. 
C urre nt/ F or mer N a me(s) or Ali as(es) P F -[ADDRESS_625639] as o utli ne d i n 
Secti o n 5. 3. 2 ( Meals a n d Dietar y  Restricti o ns). T he partici pa nts will t he n recei ve st u d y  
i nter ve nti o n at a p pr o xi matel y  0 8: 0 0 hrs ( pl us or mi n us 2 hrs) o n Da y 1. I n vesti gat or site 
pers o n nel will a d mi nister st u d y  i nter ve nti o n wit h a m bie nt te m perat ure water t o a t otal 
v ol u me of a p pr o xi m ately [ADDRESS_625640] c o nfir m t hat a p pr o priate c o n diti o ns 
(e g, te m perat ure) ha ve bee n mai ntai ne d d uri n g tra nsit f or all st u d y  i nter ve nti o n s
recei ve d a n d a n y discre pa ncies are re p orte d a n d res ol ve d bef ore use of t he st u d y  
i nter ve nti o n. 
2. O nl y  partici pa nts e nr olle d i n t he st u d y  ma y  recei ve st u d y  i nter ve nti o n a n d o nl y  
a ut h orize d site staff ma y  s u p pl y , pre pare, a n d/ or a d mi nister st u d y  i nter ve nti o n .0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
C CI C CI 
C CI C CI 
C CI C CI 
C CI 
C CI 
C CI 
C CI 
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 413. All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff. At a minimum, daily minimum and maximum temperatures for all site storage locations must be documented and available upon request. Data for non-working days must indicate the minimum and maximum temperatures since previously documented upon return to business.
4. Any excursions from the study intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery along with actions taken. The site should actively pursue options for returning the study intervention to the labeled storage conditions, as soon as possible. Once an excursion is identified, the study intervention must be quarantined and not used until [COMPANY_007] provides permission to use the study intervention. Specific details regarding the excursion definition and information toreport for each excursion will be provided to the site in the IPM.
5. Any storage conditions stated in the SRSD will be superseded by [CONTACT_78254].
6. Study interventions should be stored in their original containers.7. The investigator, institution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records), such as the IPAL or sponsor-approved equivalent. All study interventions will be accounted for using a study intervention accountability form/record.
8. Further guidance and information for the final disposition of unused study 
interventions are provided in the IPM. All destruction must be adequately documented. If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by [CONTACT_4618].
Upon identification of a product complaint, notify the sponsor within 1 business day of 
discovery as described in the IPM.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study intervention ready for administration or dispensing to the participant by [CONTACT_3436]. Dispensing is defined as the provision of study intervention, concomitant treatments, and accompanying information by [CONTACT_22806](s) to a healthcare provider, participant, in accordance with this protocol. Local health authority regulations or investigator site guidelines may use alternative terms for these activities.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge [ADDRESS_625641] u d y staff (e g, p h ys icia n, 
n urse, p h ys icia n’s assista nt, n urse practiti o ner, p har mac y  assista nt/tec h nicia n, or p har macist). 
T he ca ps ules will be pr o vi de d i n u nit d ose c o ntai ners a n d la bele d i n acc or da nce wit h [COMPANY_007] 
re g ulati o ns a n d t he cli nical site’s la beli n g re q uire me nts. 
6. 3. Assi g n me nt t o St u d y I n ter ve nti o n 
T his is a n o pe n -la bel st u d y i n w hic h eac h partici pa nt d ose d will recei ve a si n gle m g  d ose 
of P F - [ADDRESS_625642] eac h partici pa nt’s u ni q ue n u m ber assi g ne d i n c hr o n ol o gical or der of w he n i nf or me d 
c o nse nt is o btai ne d. Eac h partici pa nt w h o is d ose d wit h st u d y  i nter ve nti o n will als o be 
assi g ne d a se parate, disti nct n u m ber (as pr o vi de d t o t he site b y  t he sp o ns or), t o e na ble 
e xec uti o n of t he sp o ns or’s sta n dar d pr ocesses f or a nal y sis of P K sa m ples. 
6. 4. Bli n di n g 
T his is a n o pe n -la bel st u d y .
6. 4. 1. Bli n di n g of P a rtici p a nts 
Partici pa nts will be u n bli n de d t o t heir assi g ne d st u d y  i nter ve nti o n. 
6. 4. 2. Bli n di n g of Site Pers o n nel 
I n vesti gat ors a n d ot her site staff will be u n bli n de d t o partici pa nts’ assi g ne d st u d y  
i nter ve nti o n. 
6. 4. 3. Bli n di n g of t he S p o ns or 
S p o ns or staff will be u n bli n de d t o partici pa nts’ assi g ne d st u d y i nter ve nti o n. 
6. 5. St u d y I nter ve nti o n C o m pli a nce 
W he n t he i n di vi d ual d ose f or a partici pa nt is pre pare d fr o m a b ul k s u p pl y, t he pre parati o n of 
t he d ose will be c o nfir me d b y  a sec o n d q ualifie d me m ber of t he st u d y site staff. 
W he n partici pa nts are d ose d at t he site, t he y  will recei ve st u d y  i nter ve nti o n dir ectl y  fr o m t he 
i n vesti gat or or desi g nee, u n der me dical s u per visi o n. T he date a n d ti me of eac h d ose 
a d mi nistere d i n t he cli nic will be rec or de d i n t he s o urce d oc u me nts a n d rec or de d i n t he C R F. 
T he d ose of st u d y i nter ve nti o n a n d st u d y partici pa nt i de ntificat i o n will be c o nfir me d at t he 
ti me of d osi n g b y a me m ber of t he st u d y site staff ot her t ha n t he pers o n a d mi nisteri n g t he 
st u d y  i nter ve nti o n. St u d y site pers o n nel will e xa mi ne eac h partici pa nt’s m o ut h t o e ns ure t hat 
t he st u d y  i nter ve nti o n was i n geste d. 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) C CI 
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 43A record of the number of study intervention capsules dispensed to and taken by [CONTACT_225375].
6.6. Dose Modification
Dose modification of PF-07923568 is not allowed.
6.7. Continued Access to Study Intervention After the End of the Study
No study intervention will be provided to participants at the end of their study participation.
6.8. Treatment of Overdose
For this study, any dose of PF-07923568 greater than 1200 mg within a 24-hour time period
will be considered an overdose.
There is no specific treatment for an overdose.In the event of an overdose, the investigator/treating physician should:
1. Contact [CONTACT_185605] 24 hrs.2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities as 
medically appropriate and at least until the next scheduled follow-up.
3. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to [COMPANY_007] Safety only when associated with an SAE.5. Obtain a blood sample for PK analysis within [ADDRESS_625643] dose of 
study intervention if requested by [CONTACT_138830] (determined on a case-by-case basis).
6.9. Prior and Concomitant Therapy
All concomitant treatments taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration. All participants will be questioned about concomitant treatment at each clinic visit.
Treatments taken within [ADDRESS_625644] dose of study interventionwill be documented as concomitant treatments.
Females using hormonal contraceptives or taking hormone replacement therapy are eligible 
to participate in this study. See Appendix 4 for hormonal contraceptives that are permitted in 
this study.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 44Participants on certain medications are excluded from the study (see Appendix [ADDRESS_625645] of 
prohibited medications due to potential drug-drug interaction ).
Sites are encouraged to contact [CONTACT_486830] a 
medication is permitted or prohibited.
6.9.1. Participants in Group 1 Only (without Hepatic impairment)
In general, participants in Group 1 (without HI) will abstain from all concomitant treatments, 
except for the treatment of AEs. Of note, are the following restrictions:
!Acetaminophen/paracetamol may be used at doses of ≤1 g/day;
!Herbal supplements must be discontinued at least 28 days prior to Day 1 and until the 
follow-up;
!Limited use of prescription and nonprescription medications that are not believed to 
affect the overall results of the study may be permitted on a case-by-case basis after 
approval from the sponsor study team.
6.9.2. Participants in Groups 2-4 Only (Hepatic Impairment)
Participants in Groups 2-4 (with HI) are permitted to be on stable doses of background 
medications for the management of their concomitant medical condition(s), as long as this is in line with protocol specifications regarding prohibited medications as described above in Section 6.9 and in Appendix 9 . On a case-by-case basis, with approval from the sponsor, 
participants receiving fluctuating concomitant medication/treatment may be considered if the underlying disease is under control. Whenever possible , attempts must be made to notadd 
new medications or alter the doses and regimens of the concomitant medications after 
enrollment and for the duration of participation in this study, except in circumstances where a change is deemed medically necessary. Any changes must be captured in the CRF.
Participants may receive any permitted background medications according to their stable 
medication routine at their usual dosing times. This is with the exception of phosphate binders, antacids, and bile acid binding resins (eg, cholestyramine, colestipol), which must not be administered within the [ADDRESS_625646] on the morning of Day 1. On all other study days, participants are to receive their background medications at their usual times.
6.9.3. Rescue Medicine
There is no rescue therapy to reverse AEs observed with PF-07923568; standard medical 
supportive care must be provided to manage any AEs.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 457. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionSince this is a single-dose study, this section is NA.
7.2. Participant Discontinuation/Withdrawal from the Study
A participant may withdraw from the study at any time at their own request. Reasons for 
discontinuation from the study include the following: safety, behavioral, compliance or administrative reasons, or if the study is terminated by [CONTACT_3211].
At the time of discontinuing from the study, if possible, an early discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed.
The early discontinuation visit applies only to participants who are enrolled and then are 
prematurely withdrawn from the study. Participants should be questioned regarding their reason for withdrawal. The participant will be permanently discontinued from the study intervention and the study at that time.
If a participant withdraws from the study, they may request destruction of any remaining 
samples taken and not tested, and the investigator must document any such requests in the site study records and notify the sponsor accordingly.
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations will be performed and no additional data will be collected. The sponsor may retain and continue to use any data collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent
Participants who request to discontinue receipt of study intervention will remain in the study 
and must continue to be followed for protocol-specified follow-up procedures. The only exception to this is when a participant specifically withdraws consent for any further contact [CONTACT_219879]. Participants should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible. The withdrawal of consent should be explained in detail in the medical records by [CONTACT_093], as to whether the withdrawal is only from 
further receipt of study intervention or also from study procedures and/or post-treatment 
study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 467.3. Lost to Follow-up
A participant will be considered lost to follow-up if the participant repeatedly fails to return 
for scheduled visits and is unable to be contact[CONTACT_9298].
The following actions must be taken if a participant fails to attend a required study visit:
!The site must attempt to contact [CONTACT_14315]. Counsel the participant on the importance of maintaining theassigned visit schedule and ascertain whether the participant wishes to and/or should continue in the study;
!Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_13140]’s medical record;
!Should the participant continue to be unreachable, the participant will be considered 
to have withdrawn from the study.
8. STUDY ASSESSMENTS AND PROCEDURES
8.1. Administrative ProceduresThe investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any study-specific procedures.
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study intervention 
to confirm that they meet the study population criteria for the study. If the time between screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug shipment), then participants may be rescreened after contact [CONTACT_4490] a sponsor Clinical representative as described in Section 5.4 .090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 47Every effort should be made to ensure that protocol-required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that make it unfeasible to perform the test. In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant. When a protocol-required test cannot be performed, the investigator will document the reason for the missed test and any corrective and preventive actions that they have taken to ensure that required processes are adhered to as soon as possible. The study team must be informed of these incidents in a timely manner.
If done around the time of a blood draw, ECGs and vital sign assessments (BP and pulse rate)
should be collected before the blood draw. If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments (BP and pulse rate) should be collected beforeinsertion of the catheter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_22819].
The total blood sampling volume for individual participants in this study is approximately 
95 m. The actual collection times of blood sampling may change. Additional blood samples may be taken for safety assessments at times specified by [CONTACT_4618], provided the total volume taken during the study does not exceed 550 mL during any period of 56 consecutive days.
To prepare for study participation, participants will be instructed on the information in the 
Lifestyle Considerations and Concomitant Therapy sections of the protocol.
8.2. Efficacy Assessments
NA.
8.3. Safety Assessments
Planned time points for all safety assessments are provided in the SoA. Unscheduled safety
measurements may be obtained at any time during the study to assess any perceived safety issues.
8.3.1. Physical Examinations
A complete PE will include, at a minimum, head, ears, eyes, nose, mouth, neck, skin, heart 
and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems.
A limited PE will include, at a minimum, assessments of general appearance, the respi[INVESTIGATOR_310769], and participant-reported symptoms.
PEs may be conducted by a physician, trained physician’s assistant, or nurse practitioner as 
acceptable according to local regulation.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 48Height and weight will also be measured per the SoA and recorded in the CRF. For 
measuring weight, a scale with appropriate range and resolution is used and must be placed on a stable, flat surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only light clothing remains. They must also remove the contents of their pockets and remain still during measurement of weight.
PE findings collected during the study will be considered source data and will not be required 
to be reported, unless otherwise noted. Any untoward PE findings that are identified during the active collection period and meet the definition of an AE or SAE ( Appendix 3 ) must be 
reported according to the processes in Section 8.4.1 to 8.4.3 .
8.3.2. Vital Signs
[IP_ADDRESS]. Blood Pressure and Pulse RateBP and pulse rate will be measured as defined in the SoA.
!Single, seated BP and pulse rate will be measured with the participant’s arm 
supported at the level of the heart, and recorded to the nearest mmHg, following a rest 
of ≥5 minutes ;
!Same arm (preferably the dominant arm) will be used for BP/pulse rate assessment 
throughout the study;
!BP/pulse rate assessment should not be taken from the arm with an IV catheter, if 
placed;
!Participants should be instructed not to speak during BP/pulse rate measurements.
The same properly sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when done manually, pulse rate will be measured in the brachial/radial artery for at least30 seconds. When the timing of these measurements coincides with a blood collection, BP and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety data.
Any untoward vital sign findings that are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Section 8.4.1 to 8.4.3 .090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 498.3.3. Electrocardiograms
Single, supi[INVESTIGATOR_205722] 12-lead ECGs utilizing limb leads (with a 10-second rhythm strip) 
should be collected at times specified in the SoA section of this protocol using an ECG 
machine that automatically calculates the HR and measures PR interval, QT interval, QTcF,and QRS complex. Alternative lead placement methodology using torso leads (eg,Mason-Likar) should not be used given the potential risk of discrepancies with ECGs acquired using standard limb lead placement. All scheduled ECGs should be performed after the participant has rested quietly for at least 5 minutes in a supi[INVESTIGATOR_2547].
To ensure safety of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a post-dose QTcF interval is increased by ≥60 ms from the baseline andis >450 ms; or b) an 
absolute QT value is ≥[ADDRESS_625647] hourly until QTc values from 2 successive ECGs fall below the threshold value that triggered the repeat measurement.
If a) a post-dose QTcF interval remains ≥60 ms from the baseline andis >450 ms; or b) an 
absolute QT value is ≥500 ms for any scheduled ECG for greater than 4 hours (or sooner, at 
the discretion of the investigator); or c) QTcF value get progressively longer, the participantshould undergo continuous ECG monitoring. A cardiologist should be consulted if QTcFvalues do not return to less than the criteria listed above after 8 hrs of monitoring (or sooner, at the discretion of the investigator).
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the same positions each time in order to achieve precise ECG recordings. If a machine-read QTc value is prolonged, as defined above, repeat measurements may not be necessary if a qualified medical provider’s interpretation determines that the QTcF values are in the acceptable range.
ECG values of potential clinical concern are listed in Appendix [ADDRESS_625648] be conducted in accordance with the laboratory manual and the SoA. 
Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 50The investigator must review the laboratory report, document this review, and record any 
clinically significant changes occurring during the study in the AE section of the CRF. Clinically significant abnormal laboratory test findings are those that are not associated with the underlying disease, unless judged by [CONTACT_19448]’s condition.
All laboratory tests with values considered clinically significant and abnormal during 
participation in the study or within [ADDRESS_625649] dose of study intervention should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_219883].
If such values do not return to normal/baseline within a period of time judged reasonable by 
[CONTACT_093], the etiology should be identified and the sponsor notified.
See Appendix [ADDRESS_625650] abnormalities.
8.3.5. COVID-19 Specific Assessments
Assessment of risk for, symptoms of or testing for COVID-19 may be performed at 
screening, admission to the CRU and/or at other times during the study at investigator discretion and according to local site policies.
8.3.6. Pregnancy Testing
A serum pregnancy test is required in at screening. Following screening, pregnancy tests may 
be urine or serum tests, and must have a sensitivity of at least 25 mIU/mL. Pregnancy tests will be performed in WOCBP at the times listed in the SoA. Following a negative pregnancy 
test result at screening, appropriate contraception must be commenced and a second negative pregnancy test result will be required at the baseline visit prior to the participant’s receiving the study intervention on Day 1. Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active treatment period (or when potential pregnancy is otherwise suspected) and at the end of the study. Pregnancy tests may also be repeated if requested by [CONTACT_1202]/ECs or if required by [CONTACT_427]. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded if the serum pregnancy result is positive.
8.4. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may arise from symptoms or other complaints reported to the investigator by [CONTACT_2416] (or, when appropriate, by a caregiver, surrogate, or the participant’s legally authorized representative), or they may arise from clinical findings of the investigator or other healthcare providers (clinical signs, test results, etc.).090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 51The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue and obtain adequate information both to determine the outcome and to assess whether the event meets the criteria for classification as an SAE or caused the participant to discontinue the study (see Section 7.2 ).
During the active collection period as described in Section 8.4.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may be requested by [CONTACT_22835]-up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, which is obtained before undergoing any study-related procedure and/or receiving study intervention), through and including a minimum of [ADDRESS_625651] SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.4.[ADDRESS_625652] SAE Report Form immediately upon 090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 52awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the sponsor within 
24 hours of its being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.4.[ADDRESS_625653] to the CRF 
requirements as described in Section 5.4 .
8.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.
8.4.3. Follow-Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3 ).
In general, follow-up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety.
Further information on follow-up procedures is provided in Appendix 3 .090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 538.4.4. Regulatory Reporting Requirements for SAEs
Prompt notification by [CONTACT_63201] a study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRBs/ECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the study and will notify the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental exposure include healthcare providers, family members, and others who may be exposed. An environmental exposure may include EDP, EDB, and occupational exposure.
Any such exposures to the study intervention under study are reportable to [COMPANY_007] Safety 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
!A female participant is found to be pregnant while receiving or after discontinuing 
study intervention;
!A male participant who is receiving or has discontinued study intervention
inseminates a female partner;
!A female nonparticipant is found to be pregnant while being exposed or having been 
exposed to study intervention because of environmental exposure. Below are examples of environmental EDP:
!A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study intervention by [CONTACT_78262].090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 54The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy).
!If EDP occurs in a participant/participant’s partner, the investigator must report this 
information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP Supplemental Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until [ADDRESS_625654] dose.
!If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety using the CT SAE Report Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.
Follow-up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify [COMPANY_007] Safety of the outcome as a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless pre-procedure test findings are conclusive for a congenital anomaly and the findings are reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly in a liveborn baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to [COMPANY_007] Safety as SAEs follows:
!Spontaneous abortion including miscarriage and missed abortion should be reported 
as an SAE;
!Neonatal deaths that occur within [ADDRESS_625655] 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 55Additional information regarding the EDP may be requested by [CONTACT_456]. Further 
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner Release of Information Form to provide to his partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An EDB occurs if:
!A female participant is found to be breastfeeding while receiving or after 
discontinuing study intervention;
!A female nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study intervention (ie, environmental exposure). An example of environmental EDB is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by [CONTACT_78262].
The investigator must report EDB to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported using the CT SAE Report Form. When EDB occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study , so the 
information is not recorded on a CRF. However, a copy of the completed CT SAE Report Form is maintained in the investigator site file.
An EDB report is not created when a [COMPANY_007] drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. However, if the infant experiences an SAE associated with such a drug, the SAE is reported together with the EDB.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any instance of occupational exposure to [COMPANY_007] Safety within 
24 hours of the investigator’s awareness using the CT SAE Report Form regardless of whether there is an associated SAE. Since the information about the occupational exposure does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form must be maintained in the investigator site file.
8.4.6. Cardiovascular and Death Events
NA.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 568.4.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs 
or SAEs
NA.
8.4.8. Adverse Events of Special Interest
NA.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy is not expected in the study population.
8.4.9. Medical Device Deficiencies
NA.
8.4.10. Medication Errors
Medication errors may result from the administration or consumption of the study 
intervention by [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Medication errors are recorded and reported as follows:
Recorded on the 
Medication Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the medication errorOnly if associated with an 
SAE
Medication errors include:
!Medication errors involving participant exposure to the study intervention;
!Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
In the event of a medication dosing error, the sponsor should be notified within 24 hrs.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 57Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_625656] SAE Report 
Form only when associated with an SAE.
8.5. Pharmacokinetics
8.5.1. Plasma for Analysis of PF-07923568Blood samples of approximately 2 mL, to provide a minimum volume of 0.8 mL plasma, will
be collected into appropriately labeled tubes containing K
2EDTA for measurement of plasma 
concentrations of PF-07923568 as specified in the SoA. Whole blood aliquot (approximately 
0.15 mL) will collected from PK samples for in vivo blood/plasma ratio assessment. 
Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by [CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts
will be made to obtain the samples at the exact nominal time relative to dosing. Collection ofsamples up to and including 10 hours after dose administration that are obtained within10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) willnot be captured as a protocol deviation, as long as the exact time of the collection is noted onthe source document and the CRF. Collection of samples more than 10 hours after doseadministration that are obtained ≤[ADDRESS_625657] time of the collection is noted onthe source document and the CRF.
Samples will be used to evaluate the PK of PF-07923568. Samples collected for analyses of
plasma concentration may also be used to evaluate safety or efficacy aspects related toconcerns arising during or after the study, for metabolite identification and/or evaluation ofthe bioanalytical method, or for other internal exploratory purposes.
Genetic analyses will not be performed on these plasma samples unless consent for this was 
included in the informed consent. Participant confidentiality will be maintained.
Samples collected for measurement of plasma concentrations of PF-[ADDRESS_625658] be processed and shipped as indicated in the instructions provided to
the investigator site to maintain sample integrity. Any deviations from the PK sample
handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_486810]), including any actions taken, must be documented and reported to the sponsor.On a case-by-case basis, the sponsor may make a determination as to whether sampleintegrity has been compromised.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 588.6. Genetics
8.6.1. Specified GeneticsSpecified genetic analyses are not evaluated in this study.
8.6.2. Retained Research Samples for Genetics
A 4 mL blood sample optimized for DNA isolation Prep D1 will be collected according to 
the SoA, as local regulations and IRBs/ECs allow.
Retained Research Samples may be used for research related to the study intervention(s) and 
hepatic impairment. Genes and other analytes (eg, proteins, RNA, nondrug metabolites) may be studied using the retained samples.
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in the laboratory manual.
8.7. Biomarkers
8.7.1. Specified Gene Expression (RNA) ResearchSpecified gene expression (RNA) research is not included in this study.
8.7.2. Specified Protein Research
Specified protein research is not included in this study.
8.7.3. Specified Metabolomic Research
Specified metabolomic research is not included in this study.
8.7.4. Retained Research Samples for Biomarkers
These Retained Research Samples will be collected in this study:
!10 mL whole blood Prep B2 optimized for serum.
Retained Research Samples will be collected as local regulations and IRB/ECs allow 
according to the SoA.
Retained Research Samples may be used for research related to the study intervention(s) and 
hepatic impairment. Genes and other analytes (eg, proteins, RNA, nondrug metabolites) may be studied using the retained samples.
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in the laboratory manual and supporting documentation. 090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 598.8. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.9. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in the SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No formal statistical hypothesis testing will be performed in this study.
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis 
SetDescription
Enrolled “Enrolled” means a participant’s, or their legally authorized 
representative’s, agreement to participate in a clinical study following completion of the informed consent process and assignment to study intervention. A participant will be considered enrolled if the informed consent is not withdrawn prior to participating in any study activity after screening. Potential participants who are screened for the purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless otherwise specified by [CONTACT_760].
Safety analysis set All participants assigned to study intervention and who take at 
least [ADDRESS_625659] calculated.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 609.3. Statistical Analyses
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints.
9.3.1. General Considerations
Endpoints will be reported and analyzed according to the hepatic function group that 
participants fall into based upon their Child-Pugh score at screening.
[IP_ADDRESS]. Analyses for PK Endpoints
Natural log-transformed PK parameters (AUC
inf, Cmax, and AUC last, as data permit) will be 
analyzed using an ANOVA model including hepatic function group as fixed effect. Estimates of the adjusted means and of the adjusted mean differences (Test-Reference) with their corresponding 90% CIs will be obtained before being exponentiated to provide estimates of the adjusted geometric means and of the ratio of adjusted geometric means (Test/Reference).
9.3.2. Primary Endpoint(s) Analysis
[IP_ADDRESS]. Definition of Endpoint(s)The plasma PK parameters for PF-[ADDRESS_625660] 
quantifiable concentration (C last)Linear/Log trapezoidal method.
AUC inf* Area under the plasma 
concentration-time profile from 
time zero extrapolated to infinite 
timeAUC last+ (C last*/k el), where C last* is the 
predicted plasma concentration at the last 
quantifiable time point estimated from the 
log-linear regression analysis.
Cmax Maximum plasma concentration Observed directly from data.
Tmax Time for C max Observed directly from data as time of first 
occurrence.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 61t1/2* Terminal half-life Log e(2)/k el, where k elis the terminal phase 
rate constant calculated by a linear 
regression of the log-linear concentration-
time curve. Only those data points judged to 
describe the terminal log-linear decline will 
be used in the regression.
CL/F* Apparent clearance Dose/AUC inf.
Vz/F* Apparent volume of distribution Dose/(AUC inf∙kel).
* as data permit
The plasma concentrations of sisunatovir will be listed and descriptively summarized by [CONTACT_486831]. Individual participant and summary profiles (mean and median plots) of the plasma concentration-time data will be plotted by [CONTACT_486832], 
respectively. Mean and median profiles will be presented on both linear and semi-log scales.
Data permitting, the PK parameters listed in 
Table 4 will be summarized descriptively by [CONTACT_3148].
[IP_ADDRESS]. Main Analytical Approach
The effect of varying degrees of hepatic impairment on PK parameters will be assessed by 
[CONTACT_2164] 90% CIs around the estimated difference between each of the Test (hepatic impaired) groups and the Reference (without hepatic impairment) group. A one-way ANOVA will be used to compare the natural log transformed PF-[ADDRESS_625661], as data permit, for each of the hepatic impairment groups (Test) to the group
without hepatic impairment (Reference). Estimates of the adjusted mean differences (Test /Reference), and corresponding 90% CIs, will be obtained from the model. These will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.
Individual PF-07923568 concentrations will be listed and summarized descriptively by 
[CONTACT_374463]. Individual participant and summary profiles of the concentration-time data (using actual and nominal times, respectively) will be plotted by [CONTACT_486833]-07923568.
Box and whisker plots for individual PK parameters (AUC
inf, AUC last, and C max, if data 
permit) will be constructed by [CONTACT_486834]. PK parameters of PF-07923568 will be summarized descriptively by [CONTACT_42469].  
[IP_ADDRESS]. Supplementary Analyses
Additional analysis using linear regression may be used to analyze the potential relationship 
between appropriate PK parameters (eg, AUC
inf, AUC last, Cmax, if data permit) and hepatic 
function (eg, serum albumin concentration, PT or T bili). Plots of PK parameters (eg, AUC inf, 
AUC last, Cmax) versus hepatic function will be constructed, with a regression line and 90% 
confidence region included. Estimates of the slope and intercept, together with a 90% CI, and the coefficient of determination (ie, R-squared and adj-R-squared) may be obtained from the model.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 62Additionally, as an exploratory analysis, age and body weight may be explored as additional 
covariates/factors in the models, as appropriate.
9.3.3. Secondary Endpoint Analysis - Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, BP, pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate, following Sponsor standards.
Medical history and PE and neurological examination information, as applicable, collected 
during the course of the study, will be considered source data and will not be required to be reported, unless otherwise noted. However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported. COVID-19 specific assessments data will be considered source data and will not be required to be reported.
[IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters HR, QTcF, PR interval, and QRS complex 
will be summarized by [CONTACT_22841]. The frequency of uncorrected QT values above 500 ms will be tabulated.
The number (%) of participants with maximum post-dose QTcF values and maximum 
increases from baseline in the following categories will be tabulated by [CONTACT_3148]:
Safety QTcF Assessment
Degree of Prolongation Mild (ms) Moderate (ms) Severe (ms)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
9.3.4. Tertiary/Exploratory Endpoint(s) Analysis
[IP_ADDRESS]. BiomarkersBiomarker data from Retained Research Samples may be collected during or after the trial 
and retained for future analyses; the results of such analyses are not planned to be included in the CSR.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 639.3.5. Other Analyses
Pharmacogenomic data from Retained Research Samples may be collected during or after the 
trial and retained for future analyses; the results of such analyses are not planned to be included in the CSR.
9.4. Interim Analyses
No formal interim analysis will be conducted for this study. As this is an open-label study,
the sponsor may conduct unblinded reviews of the data during the course of the study for the purpose of safety assessment, facilitating PK modeling, and/or supporting clinical development.
9.5. Sample Size Determination
A sample size of approximately 28-32 participants (approximately 8 participants per Groups 
1-3, and 4-8 participants in Group 4 based on recruitment rate, with varying degrees of hepatic function in each of the 4 Groups) has been selected based on recommendation from the “FDA Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling”. Participants who discontinue from the study before completing all assessments may be replaced at the discretion of the investigator and sponsor.
The expected widths of the 90% CIs with 80% coverage probability are shown in Table 5 for 
a range of possible effects (Test vs Reference). The calculation assumes the selection of the default value (80%) of the tolerance parameter in the conventional calculation.
8These 
estimates are based on an assumed conservative standard deviation of 0.6 for logAUC inf(also 
applicable to logC max) based on data from previous study C5241001 part C, fed condition.
Table 5. Expected Widths of the 90% CIs (with 80% Coverage Probability) for 
Different Possible Estimated Effects
Estimated ratio 100*
Test/Referencen=8 per group
AUC
90%CI CI width
75% (42.73,131.64) 88.91
100% (56.97,175.52) 118.55
150% (85.46,263.28) 177.82
200% (113.95,351.04) 237.09
400% (227.89,702.08) 474.19090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 6410. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations10.1.1. Regulatory and Ethical ConsiderationsThis study will be conducted in accordance with the protocol and with the following:
!Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;
!Applicable ICH GCP guidelines;
!Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents 
(eg, advertisements) must be reviewed and approved by [CONTACT_456], submitted to an IRB/EC by [CONTACT_093], and reviewed and approved by [CONTACT_1201]/EC before the study is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to study participants.
The investigator will be responsible for the following:
!Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/EC;
!Notifying the IRB/EC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/EC procedures;
!Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the IRB/EC, European regulation 
536/2014 for clinical studies, European Medical Device Regulation 2017/745 for clinical device research, and all other applicable local regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_22844], or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study intervention, [COMPANY_007] should be informed immediately.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 65In addition, the investigator will inform [COMPANY_007] immediately of any urgent safety measures 
taken by [CONTACT_22845], and of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator becomes aware of.
10.1.2. Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities.Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.
10.1.3. Informed Consent Process
The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the participant and answer all questions regarding the study. The participant should be given sufficient time and opportunity to ask questions and to decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, privacy and data protection requirements, where applicable, and the IRB/EC or study center.
The investigator must ensure that each participant is fully informed about the nature and 
objectives of the study, the sharing of data related to the study, and possible risks associated with participation, including the risks associated with the processing of the participant’s personal data.
The participant must be informed that their personal study-related data will be used by [CONTACT_20004]. The level of disclosure must also be explained to the participant.
The participant must be informed that their medical records may be examined by [CONTACT_11000], by [CONTACT_6667]/EC members, and by [CONTACT_6668].
The investigator further must ensure that each study participant is fully informed about their 
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date on which the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICD.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 66Participants must be reconsented to the most current version of the IRB/EC-approved ICD(s) 
during their participation in the study as required per local regulations.
A copy of the ICD(s) must be provided to the participant.Participants who are rescreened are required to sign a new ICD.10.1.4. Data Protection
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only authorized study staff have access. The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, the study site will be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant-specific numerical code. Any participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to the sponsor will be identified by [CONTACT_20007], participant-specific code. The study site will maintain a confidential list of participants who participated in the study, linking each participant’s numerical code to their actual identity and medical record ID. In case of data transfer, the sponsor will protect the confidentiality of participants’ personal data consistent with the clinical study agreement and applicable privacy laws.
Information technology systems used to collect, process, and store study-related data are 
secured by [CONTACT_336272], alteration, or unauthorized disclosure or access.
The sponsor maintains standard operating procedures on how to respond in the event of 
unauthorized access, use, or disclosure of sponsor information or systems.
10.1.5. Committees Structure
A data monitoring committee (DMC) or independent oversight committee (IOC) will not be 
utilized.
[IP_ADDRESS]. Data Monitoring Committee
This study will not use an E-DMC.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 6710.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT/CTIS, and/or www.pfizer.com, and other public registries and websites in accordance with applicable local laws/regulations. In addition, [COMPANY_007] reports study results outside of the requirements of local laws/regulations pursuant to its SOPs.
In all cases, study results are reported by [CONTACT_4715], accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product, regardless of the geographical location in which the study is conducted. These results are submitted for posting in accordance with the format and timelines set forth by [CONTACT_20008].
EudraCT/CTIS
[COMPANY_007] posts clinical trial results on EudraCT/CTIS for [COMPANY_007]-sponsored interventional studies 
in accordance with the format and timelines set forth by [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts CSR synopses and plain-language study results summaries on www.pfizer.com 
for [COMPANY_007]-sponsored interventional studies at the same time the corresponding study results are posted to www.clinicaltrials.gov. CSR synopses will have personally identifiable information anonymized.
Documents within marketing applications
[COMPANY_007] complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary documents and CSRs including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical documents will have personally identifiable information anonymized.
Data sharing
[COMPANY_007] provides researchers secure access to participant-level data or full CSRs for the 
purposes of “bona-fide scientific research” that contributes to the scientific understanding of 
the disease, target, or compound class. [COMPANY_007] will make data from these trials available 
[ADDRESS_625662] personally identifiable information anonymized.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 68Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not be provided to applicants with significant conflicts of interest, including individuals requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries  are accurate and correct by [CONTACT_18027].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password-protected or secured in a locked room to prevent access by [CONTACT_20011].
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents. This verification may also occur after study completion. It is important that the investigator(s) and their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy, including definition of study-critical data items and 
processes (eg, risk-based initiatives in operations and quality, such as risk management and mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, virtual, or on-site monitoring), are provided in the data management plan and monitoring plan maintained and utilized by [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_625663] ensure that the records continue to be stored securely for as long as they are maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_306891].090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 69The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate with the sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor or its agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the participant’s medical records. The investigator will promptly provide copi[INVESTIGATOR_19946]. Before response submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and comment on responses to any such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the Source 
Document Locator, which is maintained by [CONTACT_456].
Description of the use of the computerized system is documented in the Data Management 
Plan, which is maintained by [CONTACT_456].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP guidelines, and all applicable regulatory requirements.
10.1.9. Study and Site Start and Closure
The study start date is the date on which the clinical study will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study 
start date.
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) regulatory authority decision, change in opi[INVESTIGATOR_1100]/EC, or change in benefit-risk assessment. Study sites will be closed upon study completion. A study site is considered 090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 70closed when all required documents and study supplies have been collected and a study -site 
closure visit has been performed.
The investigator may initiate study -site closure at any time upon notification to the sponsor
or designee/CRO if requested to do so by [CONTACT_22846]/EC or if such termination is required to protect the health of study participants.
Reasons for the early closure of a study site by [CONTACT_19711]:
!Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP guidelines;
!Inadequate recruitment of participants by [CONTACT_093];
!Discontinuation of further study intervention development.
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study agreement. If there is any conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.10. Publication Policy
For multicenter trials, the primary publication will be a joint publication developed by [CONTACT_446992](s) of the study covering all study sites. The investigator agrees to refer to the primary publication in any subsequent publications. [COMPANY_007] will not provide any financial compensation for the investigator’s participation in the preparation of the primary congress abstract, poster, presentation, or primary manuscript for the study.
Investigators are free to publish individual center results that they deem to be clinically 
meaningful after publication of the overall results of the study or [ADDRESS_625664] to the other requirements described in this section.
The investigator will provide [COMPANY_007] an opportunity to review any proposed publication or 
any other type of disclosure of the study results (collectively, “publication”) before it is submitted or otherwise disclosed and will submit all publications to [COMPANY_007] [ADDRESS_625665] proprietary information and to provide 090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 71comments, and the investigator will, on request, remove any previously undisclosed 
confidential information before disclosure, except for any study-intervention or [COMPANY_007]-related information necessary for the appropriate scientific presentation or understanding of the study results. For joint publications, should there be disagreement regarding interpretation and/or presentation of specific analysis results, resolution of, and responsibility for, such disagreements will be the collective responsibility of all authors of the publication.
For all publications relating to the study, the investigator and [COMPANY_007] will comply with 
recognized ethical standards concerning publications and authorship, including those established by [CONTACT_4717]. The investigator will disclose any relationship with [COMPANY_007] and any relevant potential conflicts of interest, including any financial or personal relationship with [COMPANY_007], in any publications. All authors will have access to the relevant statistical tables, figures, and reports (in their original format) required to develop the publication.
10.1.11. Sponsor’s Medically Qualified Individual
The contact [CONTACT_1133]’s MQI for the study is documented in the study 
contact [CONTACT_219903]/study portal or other electronic system.
To facilitate access to their investigator and the sponsor’s MQI for study-related medical 
questions or problems from non-study healthcare professionals, participants are provided with an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and study intervention identifiers, (b) participant’s study identification number, (c) site emergency phone number active 24 hours/day, 7 days per week, and (d) [COMPANY_007] Call Center number.
The ECC is intended to augment, not replace, the established communication pathways 
between the participant and their investigator and site staff, and between the investigator and sponsor study team. The ECC is only to be used by [CONTACT_336274], as a means of reaching the investigator or site staff related to the care of a participant. The [COMPANY_007] Call Center number is to be used when the investigator and site staff are unavailable. The [COMPANY_007] Call Center number is not for use by [CONTACT_240875]; if a participant calls that number directly, they will be directed back to the investigator site.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 7210.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 6. Protocol-Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
Hematocrit
RBC countMCVMCH
MCHC
Platelet countWBC countTotal neutrophils 
(Abs)
Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)
Lymphocytes (Abs)
Coagulation
aPTT,PT,INR
PT controlBUN
Creatinine (Scr)
Cystatin C (Scys)eGFR
a
Plasma Glucose (fasting)
Calcium
SodiumPotassiumChloride
Total CO
2(Bicarbonate)
ASTALTAlkaline phosphatase
GGT
Tb i l iDirect bilirubin
b,c
Indirect bilirubinb,c
Creatine kinaseb,d
Uric acidAlbuminTotal proteinpH
Glucose (qual)
Protein (qual)Blood (qual)Ketones
Nitrites
Leukocyte esteraseUrobilinogen
Urine bilirubin
Microscopy
eOther tests as part of clinical laboratory tests:
At times specified in SoA:
1. Urine pregnancy test (WOCBP only)f
At screening only:
2. Serology: HBsAg, HCVAb (if positive,
HCV RNA) and HIV
3. Serum FSH ( allfemales)
4. Serum pregnancy test ( βhCG) ( allfemales)
5. Reticulocyte count (Abs)
6. Total bile acids7. Amylase8. Lipase
At screening and Day -1 only:
9. Breath alcohol testg
10. Urine drug testh
For suspected DILI:
11. AST, ALT
12. T bili, direct and indirect bilirubin13. Total bile acids, GGT14. Albumin
15. Alkaline phosphatase
16. CK17. PT, INR18. Acetaminophen/paracetamol or protein 
adduct levels
For suspected DICI/DIKI:
19. Creatinine (Scr)
20. Cystatin C (Scys)
21. eGFRa
22. Spot (dipstick) UACR
a. eGFR should be calculated using the 2021 CKD-EPI [INVESTIGATOR_185572]-Scys combined equations, see Appendix 7 .
b. At screening and Day 1 only, unless conditions for testing are met after Day 1 per notes “c” and “d” below.
c. After Day 1, direct and indirect bilirubin assessed only when T bili is > ULN.
d. After Day 1, creatine kinase assessed only when ALT is > ULN.e. Only if urine dipstick is positive for blood, protein, nitrites or leukocyte esterase.f. Performed on-site using kits approved by [CONTACT_3211].g. Performed on-site using kits approved by [CONTACT_3211].
h. Minimum testing requirements include cocaine, THC, opi[INVESTIGATOR_414099], benzodiazepi[INVESTIGATOR_103856].
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 73Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study. Upon completion of the study, these retained safety samples may be used for the assessment of exploratory safety biomarkers or unexpected safety findings. These data will not be included in the CSR. Samples to be used for this purpose will be shipped to either a [COMPANY_007] approved BBS facility or other designated laboratory and retained for up to 1 year following the completion of the study.
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting
10.3.1. Definition of AE
AE Definition
!An AE is any untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
!Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Events Meeting the AE Definition
!Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, ECG, radiological scans, vital sign measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator. Any abnormal laboratory test results that meet any of the conditions below must be recorded as an AE:
!Is associated with accompanying symptoms;
!Requires additional diagnostic testing or medical/surgical intervention;
!Leads to a change in study dosing (outside of any protocol-specified dose 
adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy.
!Exacerbation of a chronic or intermittent preexisting condition, including an 
increase in either frequency and/or intensity of the condition.
!New condition detected or diagnosed after study intervention administration, even 
though it may have been present before the start of the study.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 74!Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
!Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an AE or SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.
Events NOT Meeting the AE Definition
!Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_19448]’s condition.
!The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the participant’s condition.
!Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is theAE.
!Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
!Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a. Results in death
b. Is life-threatening
The term “life-threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event thathypothetically might have caused death if it were more severe.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 75c. Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.
d. Results in persistent or significant disability/incapacity
!The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
!This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle), that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect
f. Is a suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic 
or non-pathogenic
The event may be suspected from clinical symptoms or laboratory findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected transmission” and “transmission” are considered synonymous. These cases are considered unexpected and handled as serious expedited cases by [CONTACT_20020]. Such cases are also considered for reporting as product defects, if appropriate.
g. Other situations:
!Medical or scientific judgment should be exercised by [CONTACT_78278], such as significant medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.
!Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 7610.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During the Active 
Collection Period
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safety throughout the active collection period. These requirements are delineated for 3 types of events: (1) SAEs; (2) nonserious AEs; and (3) exposure to the study intervention under study during pregnancy or breastfeeding, and occupational exposure.
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be completed in a consistent manner. AEs should be recorded using concise medical terminology and the same AE term should be used on both the CRF and the CT SAE Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] Safety Within 24 Hours of Awareness
SAE All All
Nonserious AE All None
Exposure to the study intervention under study during pregnancy or breastfeedingAll AEs/SAEs associated 
with EDP or EDB
Note: Instances of EDP or 
EDB not associated with an AE or SAE are not captured in the CRFAll instances of EDP are 
reported (whether or not there is an associated SAE)*
All instances of EDB are 
reported (whether or not there is an associated SAE)**
Environmental or occupational exposure to the product under study to a nonparticipant (not involving EDP or EDB)None. Exposure to a study 
non-participant is not collected on the CRFThe exposure (whether or 
not there is an associated AE or SAE) must be reported***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to [COMPANY_007] 
Safety using the CT SAE Report Form and EDP Supplemental Form; if the EDP is associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report Form.
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form, which would also include details 
of any SAE that might be associated with the EDB.
***Environmental or occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 77!When an AE or SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic reports) related to the event.
!The investigator will then record all relevant AE or SAE information in the CRF.
!It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report Form/AE or SAE CRF page.
!There may be instances when copi[INVESTIGATOR_240802]. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_346246].
!The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories:
!Mild: A type of AE that is usually transient and may require only minimal 
treatment or therapeutic intervention.  The event does not generally interfere with usual ADL.
!Moderate: A type of AE that is usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual ADL, causing discomfort,but poses no significant or permanent risk of harm to the research participant.
!Severe: A type of AE that interrupts usual ADL, or significantly affects clinical 
status, or may require intensive therapeutic intervention.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 78Assessment of Causality
!The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE or SAE. The investigator will use clinical judgment to determine the relationship.
!A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
!Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration, will be considered and investigated.
!The investigator will also consult the IB and/or product information, for marketed 
products, in their assessment.
!For each AE or SAE, the investigator must document in the medical notes that they 
have reviewed the AE or SAE and have provided an assessment of causality.
!There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the sponsor .
!The investigator may change their opi[INVESTIGATOR_486811] -follow-up 
information and send an SAE -follow-up report with the updated causality assessment.
!The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
!If the investigator does not know whether or not the study intervention caused the 
event, then the event will be handled as “related to study intervention” for reporting purposes, as defined by [CONTACT_456]. In addition, if the investigator determines that an SAE is associated with study procedures, the investigator must record this causal relationship in the source documents and CRF, and report such an assessment in the dedicated section of the CT SAE Report Form and in accordance with the SAE reporting requirements.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 79Follow -Up of AEs and SAEs
!The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically indicated or as requested by [CONTACT_456], to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other healthcare providers.
!If a participant dies during participation in the study or during a recognized 
follow-up period, the investigator will provide [COMPANY_007] Safety with a copy of any postmortem findings, including histopathology.
!New or updated information will be recorded in the originally submitted 
documents.
!The investigator will submit any updated SAE data to the sponsor within [ADDRESS_625666]
!The primary mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic DCT.
!If the electronic system is unavailable, then the site will use the paper SAE DCT
(see next section) to report the event within 24 hours.
!The site will enter the SAE data into the electronic DCT (eg, eSAE or PSSA) or 
paper form (as applicable) as soon as the data become available.
!After the study is completed at a given site, the electronic DCT will be taken 
off-line to prevent the entry of new data or changes to existing data.
!If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic DCT has been taken off-line, then the site can report this information on a paper SAE form (see next section) or to [COMPANY_007] Safety by [CONTACT_756].090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 80SAE Reporting to [COMPANY_007] Safety via the CT SAE Report Form
!Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety.
!In circumstances when the facsimile is not working, an alternative method should 
be used, eg, secured (Transport Layer Security) or password-protected email. If none of these methods can be used, notification by [CONTACT_9337] a copy of the CT SAE Report Form sent by [CONTACT_22855].
!Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.
10.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion CriteriaMale participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least [ADDRESS_625667] dose of study intervention, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s): 
!Refrain from donating sperm.
PLUS either :
!Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a longterm and persistent basis) and agree to remain abstinent. 
OR
!Must agree to use contraception/barrier as detailed below:
!Agree to use a male condom,and should also be advised of the benefit for a 
female partner to use a highly effective method of contraception, as a condom may break or leak, when having sexual intercourse with a WOCBP who is not currently pregnant.
!In addition to male condom use, a highly effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly effective methods below in Section 10.4.4 ).090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 8110.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1 ) and specify 
the reproductive requirements for including female participants. Refer to Section 10.4.[ADDRESS_625668] of contraceptive methods permitted in the study.
A female participant is eligible to participate if she (a) is not pregnant or breastfeeding; and
(b) agrees not to donate eggs (ova, oocytes) for the purpose of reproduction at least [ADDRESS_625669]; and (c) at least 1 of the following conditions applies:
!Is not a WOCBP (see definition in Section 10.4.3 ).
OR
!Is a WOCBP and agrees to use a contraceptive method that is highly effective (failure 
rate of <1% per year) with low user dependency during the intervention period and 
agrees to use it for at least [ADDRESS_625670] dose of study intervention, which corresponds to the time needed to eliminate any reproductive safety risk of the study intervention(s). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
OR
!Is a WOCBP and agrees to use a highly effective (failure rate of <1% per year) 
user-dependent method of contraception during the intervention period and for at 
least [ADDRESS_625671] dose of study intervention, which corresponds to the time needed to eliminate any reproductive safety risk of the study intervention(s). In addition to her use of the highly effective method above, she agrees to concurrently
use an effective barrier method. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, additional evaluation should be considered.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 82Women in the following categories are not considered WOCBP:
1. Premenopausal female with 1 of the following:
!Documented hysterectomy;
!Documented bilateral salpi[INVESTIGATOR_1656];
!Documented bilateral oophorectomy.
For individuals with permanent infertility due to a medical cause other than the above
(eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history interview. The method of documentation should be recorded in the participant’s medical record for the study.
2. Postmenopausal female.
!A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition:
!A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT.
!A female on HRT and whose menopausal status is in doubt will be required to 
use one of the highly effective non-estrogen hormonal contraception methods if she wishes to continue her HRT during the study. Otherwise, she must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
10.4.4. Contraception Methods
Contraceptive use by [CONTACT_22856]/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods are appropriate for this study:Highly Effective Methods That Have Low User Dependency
1. Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation.
2. Intrauterine device.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 833. Intrauterine hormone-releasing system.
4. Bilateral tubal occlusion.5. Vasectomized partner.
!Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent
6. Progestogen-only hormone contraception associated with inhibition of ovulation:
!Oral + barrier*;
!Injectable + barrier*.
7. Sexual Abstinence
Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
* Acceptable barrier methods to be used concomitantly with options 6 for the study include 
any of the following:
!Male or female condom with or without spermicide;
!Cervical cap, diaphragm, or sponge with spermicide;
!A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double-barrier methods).090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 8410.5. Appendix 5: Genetics
Use/Analysis of DNA
!Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of disease. Therefore, where local regulations and IRBs/ECs allow, a blood sample will be collected for DNA analysis.
!The scope of the genetic research may be narrow (eg, 1 or more candidate genes) or
broad (eg, the entire genome), as appropriate to the scientific question under investigation.
!The samples may be analyzed as part of a multi-study assessment of genetic factors 
involved in the response to study intervention or study interventions of this class to understand treatments for the disease(s) under study or the disease(s) themselves.
!The results of genetic analyses may be reported in the CSR or in a separate study 
summary, or may be used for internal decision making without being included in a study report.
!The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.
!The samples will be retained as indicated:
!Retained samples will be stored indefinitely or for another period as per local 
requirements.
!Participants may withdraw their consent for the storage and/or use of their Retained 
Research Samples at any time by [CONTACT_7328] a request to the investigator; in this case, any remaining material will be destroyed. Data already generated from the samples will be retained to protect the integrity of existing analyses.
!Samples for genetic research will be labeled with a code. The key between the code 
and the participant’s personally identifying information (eg, name, address) will be held securely at the study site.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 8510.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury but adapt are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a more serious potential outcome. These participants fail to adapt and therefore are “susceptible” to progressive and serious liver injury, commonly referred to as DILI. Participants who experience a transaminase elevation above 3 × ULN should be monitored more frequently to determine if they are “adaptors” or are “susceptible.”
In the majority of DILI cases, elevations in AST and/or ALT precede T bili elevations 
(>2 × ULN) by [CONTACT_22857]. The increase in T bili typi[INVESTIGATOR_161651]/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and T bili values will be elevated within the same laboratory sample). In rare instances, by [CONTACT_29623] T bili elevations are detected, AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to T bili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:
!Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bili value ≥2 × ULN 
with no evidence of hemolysis and an alkaline phosphatase value <2 × ULN or not available.
!For participants with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline:
!Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values ≥2 times the baseline values AND ≥3 × ULN; or ≥8 × ULN (whichever is 
smaller).
!Preexisting values of T bili above the normal range: T bili level increased from 
baseline value by [CONTACT_219911] ≥1 × ULN orif the value reaches ≥3 × ULN 
(whichever is smaller).090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 86Rises in AST/ALT and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferably within [ADDRESS_625672] and ALT and T bili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology. A detailed history, including relevant information, such as review of ethanol, acetaminophen/paracetamol (either by [CONTACT_20025] a co-formulated product in prescription or over-the-counter medications), recreational drug, or supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact [CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected. Further testing for acute hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary tract), and collection of serum samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted.
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 8710.7. Appendix 7: Kidney Safety: Monitoring Guidelines
10.7.1. Laboratory Assessment of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney safety monitoring requires assessment of baseline and postbaseline serum 
creatinine(Scr measurement to estimate glomerular filtration rate [Scr-based eGFR] or creatinine clearance [eCrCl]). Baseline and postbaseline serum Scys makes it feasible to distinguish AKI from other causes of Scr increase. If Scr increase is confirmed after baseline, then reflex measurement of Scys is indicated to estimate the combined Scr-Scys eGFR calculation (for adults only). In this study, eGFR will be determined using the 2021 CKD-EPI [INVESTIGATOR_185572]-Scys combined equation (see Section [IP_ADDRESS] below) and both Scr and Scyswill be measured as part of the protocol-required safety laboratory assessments at all times specified in the SoA.
Regardless of whether kidney function monitoring tests are required as a routine safety 
monitoring procedure in the study, if the investigator or sponsor deems it necessary to further assess kidney safety and quantify kidney function, then these test results should be managed and followed per standard of care.
10.7.2. Age-Specific Kidney Function Calculation Recommendations
[IP_ADDRESS]. Adults (18 Years and Above)—2021 CKD-EPI [INVESTIGATOR_185560]
9
2021 CKD-EPI
[INVESTIGATOR_185572]-Scys 
CombinedScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤0.7 if ≤0.8 eGFR = 130 × (Scr/0.7)-0.219 × (Scys/0.8)-0.323 × (0.9961)Age
Female if ≤0.7 if >0.8 eGFR = 130 × (Scr/0.7)-0.219 × (Scys/0.8)-0.778 × (0.9961)Age
Female if >0.7 if ≤0.8 eGFR = 130 × (Scr/0.7)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age
Female if >0.7 if >0.8 eGFR = 130 × (Scr/0.7)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age
Male if ≤0.9 if ≤0.8 eGFR = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.323 × (0.9961)Age
Male if ≤0.9 if >0.8 eGFR = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.778 × (0.9961)Age
Male if >0.9 if ≤0.8 eGFR = 135 × (Scr/0.9)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age
Male if >0.9 if >0.8 eGFR = 135 × (Scr/0.9)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age
10.7.3. Adverse Event Grading for Kidney Safety Laboratory Abnormalities
AE grading for decline in kidney function (ie, eGFR or eCrCl) will be according to KDIGO
criteria.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 8810.8. Appendix 8: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as AEs
!Marked sinus bradycardia (rate <40 bpm) lasting minutes.
!New PR interval prolongation >280 ms.
!New prolongation of QTcF to >480 ms (absolute) or by ≥60 ms from baseline.
!New-onset atrial flutter or fibrillation, with controlled ventricular response rate: 
ie, rate <120 bpm.
!New-onset type I second-degree (Wenckebach) AV block of >30 seconds’
duration.
!Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive ventricular 
complexes.
ECG Findings That May Qualify as SAEs
!QTcF prolongation >500 ms.
!New ST-T changes suggestive of myocardial ischemia.
!New-onset LBBB (QRS complex>120 ms).
!Newonset right bundle branch block (QRS complex>120 ms).
!Symptomatic bradycardia.
!Asystole:
!In awake, symptom-free participants in sinus rhythm, with documented periods 
of asystole ≥3.0 seconds or any escape rate <40 bpm, or with an escape rhythm 
that is below the AV node.
!In awake, symptom-free participants with atrial fibrillation and bradycardia 
with [ADDRESS_625673] 5 seconds or longer.
!Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
!Sustained supraventricular tachycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 89!Ventricular rhythms >30 seconds’ duration, including idioventricular rhythm (HR
<40 bpm), accelerated idioventricular rhythm (HR >40 bpm to <100 bpm), and monomorphic/polymorphic ventricular tachycardia (HR >100 bpm [such astorsades de pointes]).
!Type II second-degree (Mobitz II) AV block.
!Complete (third-degree) heart block.
ECG Findings That Qualify as SAEs
!Change in pattern suggestive of new myocardial infarction.
!Sustained ventricular tachyarrhythmias (>30 seconds’ duration).
!Second- or third-degree AV block requiring pacemaker placement.
!Asystolic pauses requiring pacemaker placement.
!Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
!Ventricular fibrillation/flutter.
!At the discretion of the investigator, any arrhythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and [COMPANY_007] study team, and not to be considered as all-inclusive of what to be reported as AEs/SAEs.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 9010.9. Appendix 9: Prohibited Concomitant Medications That May Result in Drug-Drug 
Interaction (DDI)
The prohibited concomitant medications listed below should not be taken with PF-[ADDRESS_625674] of drugs prohibited for potential DDI concerns with the IMP may be revised during 
the course of the study with written notification from sponsor, to include or exclude specific drugs or drug categories for various reasons (eg, emerging DDI results for the IMP, availability of new information in literature on the DDI potential of other drugs).
Strong and moderate CYP3A4 and P-gp inhibitors or inducers are prohibited, as these 
medications may have meaningful impact on the pharmacokinetics of sisunatovir.
PF-07923568 is a CYP3A4 inhibitor and therefore sensitive and narrow therapeutic index 
CYP3A4 substrates are also prohibited in this study. Since based on in vitro data PF-07923568 may be a weak inhibitor of CYP2B6, sensitive narrow TI substrates of CYP2B6 are excluded.
PF-07923568 also may be an inhibitor of OCT1 and MATE1 transporters; therefore, 
sensitive substrates of these transporters are excluded.
Although his is not all-inclusive, a list of medications that are prohibited in this study is 
provided below. Site staff should consult with the sponsor or designee with any questions regarding potential DDI.
Investigators should consult the product label for any other medication used during the study 
for information regarding medication that is prohibited for concomitant use.
Prohibited Concomitant Medications
CYP3A Inhibitors CYP3A Inducers
Moderate Strong Moderate Strong
Aprepi[INVESTIGATOR_486812]. John’s wort
Erythromycin Ketoconazole
Fluconazole Lopi[INVESTIGATOR_486813]090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 91Tofisopam Posaconazole
Verapamil Ritonavir
Saquinavir
Telaprevir
Tipranavir
Telithromycin
Troleandomycin
Voriconazole
Sensitive CYP3A Substrates CYP3A Substrates 
with Narrow Therapeutic Index
Alfentanil Lovastatin Alfentanil
Atorvastatin Lurasidone Astemizole
Avanafil Maraviroc Cisapride
Budesonide Midazolam Cyclosporine
Buspi[INVESTIGATOR_486814]1 Substrates
Metformin
Sensitive CYP2B6 Substrates CYP2B6 Substrates 
with Narrow Therapeutic Index
Velpatasvir Cyclophosphamide
P-gp Inhibitors P-gp Inducers
Atazanavir Lopi[INVESTIGATOR_486815]. John’s wort (hypericum perforatum) extract
Diltiazem Ritonavir Tipranavir
elvitegravir and cobicistat 
and emtricitabine and 
tenofovir DFSaquinavir Verapamil
Erythromycin Telaprevir
glecaprevir and pi[INVESTIGATOR_486816]-inclusive list.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 9210.10. Appendix 10: Child-Pugh Classification of Liver Dysfunction
Table 7. Scoring for Child-Pugh Classification10
Group Child-Pugh 
ScoreLevel of 
DysfunctionTotal Score
(tally based on assessment of 
parameters in Table 8)
1 Not Applicable Without hepatic 
impairmentNot Applicable
2 A Mild 5-6
3 B Moderate 7-9
4 C Severe ≥10
Table 8. Derivation of Child-Pugh Classification Score
Assessment Parameters Assigned score for observed findings
1 point 2 points 3 points
Encephalopathy gradea
(refer to Table 9 below)0 1 or 2 3 or 4a
Ascites Absent Asymptomatic Requiring intervention
Serum T bili, mg/dL <2 2 to 3 >3
Serum albumin, g/dL >3.5 2.8 to 3.5 <2.8
PT, sec prolonged <4 4 to 6 >6
a. Participants with a prior history of Grade 3 or 4 encephalopathy who are currently receiving 
an intervention [ eg,lactulose or lactitol, alone or in combination with rifaximin, and/or neomycin] to 
manage encephalopathy related signs and symptoms should be scored for encephalopathy grading based 
on their presentation while on intervention at the screening visit and can be incl uded in Study C5241012
as long as they do nothave clinically active Grade 3 or 4 encephalopathy.
Table 9. Determination of Encephalopathy Grade
Encephalopathy Grade Definition
0 Normal consciousness, personality, neurological exam
1 Restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting
[ADDRESS_625675]-disoriented, hyperactive reflexes, rigidity
4aUnrousable coma, no personality/behavior, decerebrate
a. Participants with clinically active Grade 3 or 4 encephalopathy are excluded.090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 9310.11. Appendix 11: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
Abs absolute
ADL activity/activities of daily living
AE adverse event
AKI acute kidney injury
ALP alkaline phosphatase
ALT alanine aminotransferase
ANOVA analysis of variance
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the concentration-time curve
AUC [ADDRESS_625676] quantifiable concentration
AUC tau area under the plasma concentration-time profile over tau, the dosing interval, where tau = [ADDRESS_625677]
#-hCG #-human chorionic gonadotropin
BBS Biospecimen Banking System
BID twice daily
BMI body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD-EPI [INVESTIGATOR_486817], plasma
CL/F apparent clearance of drug from eg, plasma
Clast last quantifiable concentration
Cmax maximum plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID-19 coronavirus disease 2019
CPC Child-Pugh Classification090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 94Abbreviation Term
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR Clinical Study Report
CT clinical trial
CTIS Clinical Trial Information System
CT scan computed tomography scan
CV cardiovascular
CYP cytochrome P450
DBP diastolic blood pressure
DCT data collection tool
DDI drug-drug interaction
DIC Drug in Capsule
DICI drug-induced creatinine increase
DIKI drug-induced kidney injury
DILI drug-induced liver injury
DPB Dry Powder Blend
EC ethics committee
ECC emergency contact [CONTACT_486835]
E-DMC External Data Monitoring Committee
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
eSAE electronic serious adverse event
EU European Union
EudraCT European Union Drug Regulating Authorities Clinical Trials 
(European Clinical Trials Database)
FIH first-in-human
FSH follicle-stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GI gastrointestinal
H hour
HAE hypoglycemic adverse event
HBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HI hepatic impairment
HIV human immunodeficiency virus
HR heart rate090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 95Abbreviation Term
hrs hours
HRT hormone replacement therapy
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ID identification
ICU intensive care unit
IMP investigational medicinal product
IND Investigational New Drug
INR international normalized ratio
IPAL Investigational Product Accountability Log
IPM investigational product manual
IRB Institutional Review Board
IV intravenous(ly)
K2EDTA dipotassium ethylene diamine tetraacetic acid
kel first-order elimination rate constant
KDIGO Kidney Disease Improving Global Outcomes
LBBB left bundle branch block
LFT liver function test
LRTI lower respi[INVESTIGATOR_486818]1 multidrug and toxin exclusion protein [ADDRESS_625678] octamer binding transcription factor
PD pharmacodynamic(s)
PE physical examination
P-gp P glycoprotein
PK pharmacokinetic(s)
PSSA [COMPANY_007]'s Serious Adverse Event Submission Assistant
PT prothrombin time
PVC premature ventricular contraction/complex090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
PF-07923568
Protocol C5241012Final Protocol, 23 February 2023
PFIZER CONFIDENTIAL
CT02-GSOP Clinical Pharmacology Protocol Template (01 April 2022)
Page 96Abbreviation Term
QTc corrected QT interval
QTcF QTc corrected using Fridericia’s formula
qual qualitative
RBC red blood cell
RSV CV respi[INVESTIGATOR_486819]-CoV-[ADDRESS_625679] identifier
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
t½ terminal phase half-life
T bili total bilirubin
TEAE treatment-emergent adverse event
THC tetrahydrocannabinol
TI therapeutic index
Tmax time to reach C max
UACR urine albumin/creatinine ratio
ULN upper limit of normal
US [LOCATION_002]
VS vital signs
Vz/F apparent volume of distribution
WBC white blood cell
WOCBP woman/women of childbearing potential090177e19cb785b2\A pproved\A pproved On: 24-Feb-2023 02:23 (GMT )
P F -0 7 9 2 3 5 6 8 
Pr ot oc ol C 5 2 4 1 0 1 2 
Fi nal Pr ot oc ol, 2 3 Fe br uar y 2 0 2 3 
P FI Z E R C O N FI D E N TI A L 
C T 0 2 -G S O P Cli nical P har mac ol o g y Pr ot oc ol Te m plate ( 0 1 A pril 2 0 2 2) 
Pa ge 9 7 1 1. R E F E R E N C E S 
1. F D A. G ui da nce f or i n d ustr y : p har mac o ki netics i n patie nts wit h i m paire d he patic 
f u ncti o n: st u d y  desi g n, data a nal ys is, a n d i m pact o n d osi n g a n d la beli n g . Ma y  2 0 0 3. 
Accesse d: [ADDRESS_625680] Dis 
T her. 2 0 1 8; 7( 1): 8 7 - 1 2 0. 
3. Li Y , Wa n g X, Bla u D M, et al. Gl o bal, re gi o nal, a n d nati o nal disease b ur de n esti mates 
of ac ute l o wer res pi[INVESTIGATOR_1305] y i nfecti o ns d ue t o res pi[INVESTIGATOR_1305] y s y n c y tial vir us i n c hil dre n 
y o u n ger t ha n 5 y ears i n 2 0 1 9: a s y ste matic a nal ys is. L a ncet. 2 0 2 2; 3 9 9( 1 0 3 4 0): 2 0 4 7 - 6 4. 
4. R ha B, C ur ns A T, Li vel y J Y, et al. Res pi[INVESTIGATOR_1305] y s y nc y tial vir us -ass ociate d 
h os pi[INVESTIGATOR_1314] o ns a m o n g y o u n g c hil dre n : 2 0 1 5 -2 0 1 6. Pe diatrics. 2 0 2 0; 1 4 6( 1). 
5. La n gle y  J M, Bia nc o V, D o mac h o ws ke J B, et al. I nci de nce of res pi[INVESTIGATOR_1305] y  s y n c y tial vir us 
l o wer res pi[INVESTIGATOR_1305] y  tract i nfecti o ns d uri n g t he first 2 ye ars of life : a pr os pecti ve st u d y  
acr oss di verse gl o bal setti n gs . J I nfect Dis. 2 0 2 2; 2 2 6( 3): 3 7 4 - 8 5. 
6. J ha A, Jar vis H, Fraser C, et al . Res pi[INVESTIGATOR_1305] y  s y n c y tial vir us . I n: H ui D S, R ossi G A, 
J o h nst o n S L , e ds. S A R S, M E R S a n d ot her Viral L u n g I nfecti o ns. S heffiel d ( U K) [ADDRESS_625681] Dis. 2 0 1 7; 6 5( 6): 1 0 2 0- 5. 
8. [COMPANY_007]. . Sa m ple size calc ulati o n: cr oss -o ver trials t o 
de m o nstrate bi oe q ui vale nce or esti mate bi oa vaila bilit y . Cli nical bi ostatistics tec h nical 
re p ort # 5. 1 ( Versi o n Date: A pril 2 4, 2 0 0 2). 
9. I n ker L A , E nea n y a N D, C ores h J ,et al. Ne w creati ni ne -a n d cys tati n C - b ase d eq uati o ns 
t o esti mate G F R wit h o ut r ace. N E n gl J Me d. 2 0 2 1; 3 8 5: 1 7 3 7 - 4 9. 
1 0. P u g h R N, M urra y -L y o n I M, Da ws o n J L,  et al. Tra nsecti o n of t he oes o p ha g us f or 
blee di n g oes o p ha geal varices. Br J S ur g. 1 9 7 3; 6 0( 8): 6 4 6 - 9. 0 9 0 1 7 7 e 1 9 c b 7 8 5 b 2\ A p pr o v e d\ A p pr o v e d O n: 2 4- F e b- 2 0 2 3 0 2: 2 3 ( G M T) P P D 